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The enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are
inhibited by nerve agents such as sarin and tabun. In general, the inhibited enzymes are
reactivated by bisquaternary ammonium compounds (oximes). The binding free energies
of the oximes; 2-PAM, MMB-4, HI-6, and obidoxime bound to human AChE (hAChE)
and human BChE (hBChE) inhibited by sarin and tabun and also to the uninhibited
enzymes were calculated using various computational methods.
Using thermodynamic integration, the binding free energies of all the inhibited
and uninhibited systems of MMB-4 and obidoxime were evaluated. The standard
binding free energies (dA) were more negative than the experimental values due to
limitations of the ff99 forcefield. The RMS error of dA for the inhibited systems of
MMB-4 was 2.1 kcal/mol, and for obidoxime systems it was 4.8 kcal/mol with respect to
the experimental free energies.
The binding enthalpies calculated using MM-GBSA and MM-PBSA methods for
2-PAM, MMB-4, HI-6, and obidoxime systems were negative, except for hBChE-sarinMMB-4 and hBChE-sarin-obidoxime. For all the systems the TdS values calculated

using normal mode analysis were equal to or lower in magnitude than their corresponding
binding enthalpies. As a result, the estimated free energies were positive for most of the
systems. Clearly, the present algorithms cannot effectively estimate the binding entropies
for a protein-ligand system. Met81 has commonly shown favorable interactions, and
lysine or arginine exhibited unfavorable interactions with the reactivator in all the
systems.
Second, the interactions between chloropyrifos-oxon (Cpo) and experimentally
tested neutral and monopyridinium oximes bound to the Q192 or R192 polymorphs of
human paraoxonase1 (hPON1) were studied. The equilibrated Q192 and R192 hPON1
were structurally different than the crystal structure of recombinant PON1. The neutral
oximes have shown more favorable interactions with Cpo in Q192 hPON1 + Cpo system
compared to R192 hPON1 + Cpo. Whereas the monopyridinium oximes interacted more
affectively with Cpo in R192 hPON1 than Q192 hPON1. The relative deprotonation
energy of the monopyridinium oxime was lower than the neutral oxime. Hence, the
monopyridinium oxime can hydrolyze an organophosphate at a higher rate than a neutral
oxime.
KEYWORDS: AChE, BChE, thermodynamic integration, MM-GBSA, MM-PBSA,
normal mode analyses, chloropyrifos-oxon, neutral oximes,
monopyridinium oximes
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CHAPTER I
INTRODUCTION

1.1

Introduction
The enzymes acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase

(BChE, EC 3.1.1.8) belong to the family of cholinesterases.1 Both AChE and BChE are
inhibited by the organophosphates (OP’s) such as nerve agents, i.e. sarin, tabun, soman,
etc.2-4 Nerve agents can harm human beings and other living species.5-7 For 50 years,
pyridinium oximes have been used to treat inhibited cholinesterases for OP exposure.8-9
In order to understand the inhibition process and to validate the reactivation efficiency of
various oximes, the tertiary structural information of AChE and BChE must be known.
Many crystal structures of AChE such as torpedo californica, mouse, human, etc.
have been reported in the literature.10-14 However, only a handful of BChE structures are
known (34 crystal structures were found in the protein data bank as of 2013). The
enzymes AChE and BChE are structurally similar.15-16 The existence and function of
AChE was first proposed by Dale in 1914.17 AChE mainly hydrolyzes the
neurotransmitter acetylcholine (ACh) into acetic acid and choline in the postsynaptic
vesicle.18 On the other hand, BChE also hydrolyzes ACh and other molecules such as
butyrylcholine.19 It hydrolyzes a wide range of toxic esters: cocaine, heroin, and
pesticides.19-21

1

1.2

Acetylcholinesterase
The crystal structure of AChE derived from torpedo californica (tAChE) has

provided a wealth of information regarding the important regions of the enzyme.11 The
active site is located at the bottom of a 20 Å deep gorge. The gorge contains 14 aromatic
residues, which provide extra stability to the incoming ligands through electrostatic and
van der Waals interactions.10,22-25 The active site contains a catalytic triad Glu-His-Ser.10
Furthermore, the oxyanion hole26 and the peripheral anionic site27-28 influence the
incoming ligand and its interaction with the catalytic serine. The ligand often interacts
with the residues of the peripheral anionic site (present at the entrance of the gorge) and
hence partially blocks the gorge entrance.18,29 Sussman et al.10 have suggested that
certain bulky aromatic compounds cannot fit into the gorge and thereby interact with the
peripheral anionic site residues. But OP’s and monoquaternary and bisquaternary
pyridinium compounds can enter and interact with the catalytic serine.
As mentioned earlier, the main function of AChE is to hydrolyze ACh. The
breakdown of ACh occurs in two steps: acylation and deacylation.30-34 The mechanism
involving acylation and deacylation are shown in Figure 1.1. There exists a strong
hydrogen bond between the H atom of the active site serine-OH and N at the Ɛ position of
the catalytic His, which leads to the deprotonation of the serine. Simultaneously, Ser-Oattacks the carbonyl carbon of the choline ester. Hence, choline gets liberated. A
hydrogen bond between H of the δN on histidine and an O of COO- on the glumate also
exists (both His and Glu are catalytic residues). During the acylation process, the
carbonyl O of the ACh forms hydrogen bonds with the oxyanion residues. Then, in the

2

second step a water molecule attacks the acylated enzyme, restoring the enzyme activity
by liberating acetic acid.

Figure 1.1

Hydrolysis process of ACh

The acylation and deacylation steps of the ACh hydrolysis process are catalyzed by
AChE.
1.3

Organophosphates
Organophosphates are phosphorous-containing organic compounds and are

generally used as pesticides and nerve agents.4,35-37 Immediately previous to and during
World War II, Germany developed nerve agents to target humans.38,39 The first nerve
agent, tabun (1935),40,41 was synthesized by Schrader’s group, followed by sarin in
1938,41 upon the insistence of the Nazi government. Soman (1944)40 was synthesized by
Richard Kuhn in Germany. Later, VX 42 was synthesized by Tammelin (1957) in the
United Kingdom. The structures of soman, sarin, tabun, and VX are shown in Figure 1.2.
Iraq used nerve agents to kill its own Kurdish population, and Iranian soliders during the
Iran-Iraq war (1980’s).43,44 Nerve agents were also used during the terrorist attacks in
Japan (1995).45
3

Figure 1.2

The nerve agents 1) soman, 2) sarin, 3) tabun, and 4) VX

Nerve agents inactivate AChE by phosphonylating the active site serine.3,46 As a
result, the breakdown of ACh is prevented. Thus, ACh accumulates in the neuronal
synapses and neuromuscular junctions, causing paralysis, seizures, and other cholinergic
syndromes.47-49
1.4

Mechanism of inhibition
The nerve agents are electrophilic in nature. During the phosphonylation process,

a covalent bond is formed between the nerve agent and the active site serine.50-52 The
inhibition process is a two-step mechanism and is shown in Figure 1.3. Initially, Ser-Oattacks the P atom of the nerve agent. Then, an OP-serine pentacoordinated intermediate
is formed. In the second step, the leaving group gets detached from the OP-serine
complex.
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Figure 1.3

Reaction pathway of a nerve agent inhibiting the active site serine of AChE

where L = the leaving group
1.5

Oximes as reactivators
The inhibited OP-serine complex undergoes aging or reactivation. Aging is an

irreversible process, wherein the activity of the enzyme is permanently lost.53,54 As
shown in Figure 1.2, the nerve agents has a P-O-R moiety. During the aging process, the
O-R bond gets dissociated in the presence of a water molecule as shown in Figure 1.4.
Due to the cleavage of the O-R bond, a negative charge is formed on the OP-serine
adduct. The enzyme cannot be reactivated because the negative charge inhibits the
nucleophilic attack. Therefore, before the enzyme undergoes aging it has to be
reactivated. Generally, a reactivator, i.e. a bispyridinium quaternary ammonium salt
(oxime), is introduced into the active site.55,56 The oxime breaks the OP-serine bond and
removes the nerve agent from the active site.

Figure 1.4

The aging process of AChE in the presence of a water molecule
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Eberhard Gross experimentally showed that atropine can be used for treatment of
nerve agent exposure.42 However, it was observed that atropine is only a good
antimuscarnic agent but not a reactivating agent.36,57,58 In 1951, Wilson showed that
hydroxylamine reactivates AChE phosphanylated with tetraethylpyrophosphate.59 Later,
a new class of antidotes, molecules containing quaternary ammonium groups, was
developed, which can reactivate AChE against OP exposure. 2-PAM was proven to be a
better reactivator than hydroxylamine.47,60,61 Some of the in vitro experiments have
shown that 2-PAM cannot efficiently reactivate cholinesterases against sarin, cyclosarin,
tabun, paraoxon, and VX exposure.62-65 So, newer oximes (TMB-4,66 obidoxime,47,67
HI-6,68,69 HLö7,70 and MMB-471) were synthesized. The structures of 2-PAM, TMB-4,
obidoxime, HI-6, HLö7, and MMB-4 are shown in Figure 1.5.

Figure 1.5

Structures of monoquaternary and bisquaternary ammonium compounds

1) 2-PAM, 2) TMB-4, 3) obidoxime, 4) HI-6, 5) HLö7, and 6) MMB-4
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The current standard treatment for nerve agent exposure is giving the patient
atropine and an oxime (2-PAM or obidoxime).72,73 Atropine blocks the overstimulation
caused by the excess ACh at the peripheral muscarinic receptors, whereas the oxime
restores the activity of the enzyme.58,74 The oxime reactivation mechanism is not well
understood. The most widely accepted mechanism for oxime reactivation is similar to
inhibition process and is shown in Figure 1.6.36,75,76

Figure 1.6

Oxime reactivation mechanism

Several in vitro and in vivo rat models and in vivo guinea pigs models were
studied to analyze the effectiveness of newer oximes against various nerve agent
exposures.58,77-81 The efficacy of the oximes against nerve agents cannot be tested on
humans due to ethical issues. Therefore, only a few human erythrocyte in vitro models
are currently available.56,82,83 Unfortunately, no universal antidote is available for all
nerve agent exposures.
Worek et al. showed that HI-6 cannot reactivate AChE effectively against tabun
exposure.84 In fact, tabun-inhibited AChE and BChE are highly resistant towards
reactivation.85-87 The reactivation of tabun-inhibited AChE or BChE takes longer than
sarin or VX-inhibited cholinesterases.88 It has been suggested that the lone pair of
7

electrons present on the amide group of tabun inhibits the nucleophilic attack of the
oxime.87 However, HI-6 can effectively reactivate AChE inhibited by sarin and
soman.69,88 One of the limitations of HI-6 is its poor stability in an aqueous medium.89,90
Therefore, some countries, like Canada, are using a powdered form of HI-6 in an autoinjector. Obidoxime can efficiently reactivate AChE and BChE against sarin and
tabun.56,62,63,88 MMB-4 has shown promising results in reactivating inhibited
cholinesterases.52,77,91,92 In some of the in vitro models, MMB-4 has shown higher
reactivation efficiency than 2-PAM and HI-6 while reactivating AChE inhibited by sarin,
cyclosarin, tabun, and VX.83,93-95
In order to efficiently reactivate the inhibited cholinesterases, oximes should meet
certain structural requirements. Using an in vitro model (rat brain), Kuca et al. tested the
efficiency of 2-PAM, obidoxime, HI-6, MMB-4, TMB-4, and HLö7 on AChE inhibited
by soman, tabun, cyclosarin, sarin, and VX.57 Based on their analysis, they have
suggested that the oxime reactivating efficiency depends on the following criteria:
a) Presence of quaternary nitrogen in the reactivator
The quaternary nitrogen increases the reactivation efficiency of the oxime.
Binding affinities of bisquaternary ammonium salts (HI-6, MMB-4, etc.) to
cholinesterases inhibited by nerve agents are higher compared to mono-quaternary
compounds, i.e., 2-PAM.80, 96-98
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b) Rigidity of the linker
The linker attaches two pyridinium rings of a reactivator. The reactivation
efficiency of an oxime decreases if the linker is not flexible, since a rigid molecule cannot
orient properly in the active site, in order to break the OP-serine bond.57
c) Oxime group
The oxime group is a strong nucleophile and has the ability to break the OP-serine
bond. As a result, the OP gets detached from the active site, and the activity of the
protein gets restored.
d) Position of oxime group on the pyridinium ring
The position of the oxime group attached to the quaternary pyridinium ring plays
an important role in the reactivation process. An oxime group present at a para or ortho
position relative to the quaternary nitrogen exhibits a higher reactivation rate compared to
an oxime at a meta position.62,94,99,100
e) Number of oxime groups in the reactivators
There is no generalized rule for the number of oxime groups. The reactivator
should have at least one oxime group.57
Numerous in vivo and in vitro studies and a very few clinical trials have been
carried out for analyzing the reactivation efficiency of various oximes. None of the
presently available oximes can effectively reactivate inhibited AChE or BChE against all
nerve agent exposures. A lot of time and money are involved in testing the efficiency of
oximes in trials. Therefore, computational tools can be used to verify the reactivation
efficiency of oximes. The efficiency of various oximes can be explored by calculating
9

the free energy of binding and comparing them against each other. These analyses will
also provide new insights about various oxime conformations, their interactions, and their
spatial orientations in the active site.
An alternative route to address nerve agent exposure is to increase the rate of
nerve agent detoxification. This can prevent the inhibition of AChE or BChE upon nerve
agent exposure to some extent. A detailed description of this process is discussed below.
1.6

Paraoxonase 1
The mammalian enzyme paraoxonase (PON) exists in three isoforms: PON1,

PON2, and PON3.101,102 Both PON1 and PON3 are mainly found in the liver, whereas
PON2 is located in many tissues.103,104 PON1 is extensively studied, as it hydrolyzes a
wide variety of molecules.105-107 PON1 is synthesized in the liver and gets secreted into
the blood stream.103 It further gets attached to a high density lipoprotein (HDL) particle
containing apolipoprotein A1 (apo-A1).108-110 Apo-A1 increases the stability and the
hydrolysis process of PON1.111,112 PON1 bound to HDL particles decreases the risk of
atherosclerosis.113-116
PON1 was characterized by Aldridge in 1953 as an “A” esterase enzyme, which
can hydrolyze paraoxon. On the other hand, “B” esterases, i.e. cholinesterases, are
inhibited by paraoxon.117,118 Uriel in 1961 detected the activity of PON1 in an immunoprecipitate of HDL particles.119 The main function of PON1 is to hydrolyze lactones
produced during lipid oxidation.120,121 Additionally, it can also hydrolyze
organophosphates, i.e. paraoxon, chlorpyrifos-oxon (active metabolites of parathion and
chloropyrifos), etc., and nerve agents such as sarin, soman, and VX.104-107,122 Therefore,
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PON1 plays an important role in lowering the toxicity of nerve agents. The structures of
paraoxon and chlorpyrifos-oxon are shown in Figure 1.7.

Figure 1.7

1.7

Structures of paraoxon and chlorpyrisfos-oxon

Structure of PON1
The crystal structure of pure human PON1 has not yet been determined. Human

PON1 is unstable and insoluble, and it aggregates in the absence of detergents.104,123 In
general, human PON1 exhibits a R192Q polymorphism, influencing the catalytic
properties of the protein.124,125 The R192 form of PON1 hydrolyzes both paraoxon and
chlorpyrifos-oxon more efficiently than Q192.107,126,127
Harel et al. (PDB ID: 1V04) reported the crystal structure of a recombinant PON1
(rePON1).104 It was obtained by shuffling the PON1 genes of rabbit, human, rat, and
mouse. The primary sequence identity between rePON1 and wild-type rabbit was about
91%. Similarly, wild-type human and rabbit PON1 sequences are also closely related to
each other (86%).103 The active site and catalytic activity of rePON1 were similar to
wild-type rabbit and human enzymes. In order to increase the solubility, mutations were
made in the exterior regions of rePON1 that did not affect its enzymatic activity. The
1V04 structure was determined at pH 4.5, where the enzyme is biologically inactive. In
11

2012, David et al. determined two crystal structures of rePON1 at pH 6.5 (active).128 The
first structure (PDB ID: 3SRE) contains a phosphate ion in the active site, whereas the
second one (PDB ID: 3SRG) contains 2-hydroxyquinoline, which is considered to be a
strong inhibitor of PON1, along with a phosphate ion.
PON1 is a six-bladed β-propeller containing two Ca2+ ions in the central tunnel as
shown in the Figure 1.8. The catalytic Ca2+ ion lies in the bottom of the active site. The
Ca2+ ions maintain the structural stability and play a major role in the catalytic
mechanism of the protein.104,128,129 The N-terminus (H1 loop, residues 1-18) is highly
hydrophobic and is anchored into the HDL particle.103,104,130 Similarly, the H2 loop
(residues 182-196) is in contact with the membrane layer. It was observed that residue
Y71 was facing towards (inwards) the active site in the presence of a ligand and outwards
in its absence. The surface loop (72-79) and Y71 influence the entrance of the ligand into
the active site.128 The protein exhibits closed and open conformations depending upon
the movement of the flexible surface loop. In a ligand-bound protein, the surface loop is
structured and acts as a lid to the active site (closed conformation). As a result, the active
site becomes narrow. In the absence of a ligand, the loop is disordered, and the protein
exists in an open conformation. In all three crystals of rePON1, the anchored loop (H1
loop) was not resolved. The conformation of the surface loop was properly described
only in the 3SRG structure.
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Figure 1.8

1.8

Structure of Q192 human PON1

Hydrolysis mechanism
Harel et al. showed that the hydrolysis of lactones, arylesters, and

organophosphates occurs by a nucleophilic attack of a hydroxide ion (formed from a
water molecule) in the active site.104 During this process, the O atom of C=O of lactones
or P=O of organophosphates must be close to the catalytic Ca2+. The catalytic Ca2+ ion
pulls the electron density present on the O of C=O or P=O towards it. The deprotonation
of water in the active site is poorly understood. The hydroxide ion is a moderately strong
nucleophile. Therefore, the hydrolysis rates of paraoxon, chlorpyrisfos-oxon, and nerve
agents are rather slow.107,131,132 David et al. have shown that the His115/His134 dyad
deprotonates the water molecule during the hydrolysis of lactones or arylesters.128 The
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general mechanisms for the hydrolysis of lactones and esters are shown in Figure 1.9 a)
and 1.9 b).

Figure 1.9

Hydrolysis mechanism of a) lactones and b) esters

In the case of organophosphate hydrolysis, the deprotonation step is still not clear.
One suggested mechanism is that D269 of PON1 acts as a nucleophile and forms a
covalent bond with the organophosphate, followed by a nucleophilic attack of a
hydroxide ion.133-135 This mechanism is similar to the inhibition and reactivation
processes of cholinesterases. However, unlike cholinesterase, PON1 does not undergo
aging.136 Hence, this mechanism is not widely accepted. Some computational studies
have shown that E53 or D269 or both may be involved in the deprotonation of
water.123,137 The hydrolysis of organophosphates involves the formation of a
pentacoordinated intermediate, as compared to the tetracoordinated intermediate in
lactones and arylesters shown in Figure 1.3.
Since PON1 is a promiscuous protein, understanding and analyzing
organophosphate hydrolysis is essential. Further, to enhance the hydrolysis process, new
ligands can be computationally tested and experimentally verified.
14

1.9

Research Goals
This research project consists of two major parts. The main goals of the two parts

are described below.
The goals of the first part are to determining the oxime free energy of binding in
human AChE and BChE inhibited by nerve agents using thermodynamic integration (TI);
to explore alternative methods for calculating free energy of binding; to compare the
oxime free energy of binding calculated using TI with the alternative methods and also
with available experimental values; and to identify important active site residues which
participate in the reactivation process. The goals of the second part are to construct a
model of the 3D structures of Q192 and R192 human PON1 (hPON1) using homology
modeling; to perform docking studies to analyze the orientation and the binding
interactions of chlorpyrifos-oxon (Cpo) with the active site residues of hPON1; and to
dock a variety of neutral and monopyridinium oximes into the active site of the complex
(hPON1+ Cpo). This novel study will be useful to computationally identify a few oximes
which show favorable interactions with the complex.
Basic background information about MD simulations, various methods for
calculating protein-ligand free energy of binding, and a brief description of docking
studies are discussed in Chapter 2. The results and discussion of oximes’ free energies of
binding are explained in Chapters 3 and 4. Similarly, the outcomes of human PON1+
Cpo docking studies are explained in Chapter 5. Finally, the overall conclusions of the
research are discussed in Chapter 6.
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CHAPTER II
METHODS

This chapter is broadly divided into three sections: introduction to molecular
dynamics simulations, free energy methods, and docking studies.
2.1

Introduction to molecular dynamics simulations
The role of computational simulations is significantly increasing in various fields,

for example, pharmacology, drug design, materials science, interstellar chemistry, etc.138141

For the last few decades computer storage capacity and processor speed have

tremendously increased.142,143 As a result, high performance computing centers equipped
with thousands of processors and data storage capacity on the order of terabytes or
petabytes are being established all over the world.142 So, scientists belonging to various
fields are designing algorithms and software for solving challenging and interesting
scientific problems.144-146
A variety of theoretical/computational methods and models have been developed
to explain, cross check, and illustrate various theories and experimental results.146-150
Molecular modeling is one such computational technique. It is categorized into quantum
mechanics and molecular mechanics. Quantum mechanics are used to calculate bond
dissociation energies, conformational analysis, geometry optimization, transition state,
etc. for molecules containing less than 500 atoms using different theoretical methods.151
16

Similarly, molecular mechanics are used to analyze thermodynamic and kinetic
properties of macromolecules (proteins and nucleic acids) based on Newton’s second law
of motion.152,153 Two important branches of molecular mechanics are Molecular
Dynamics (MD) and Monte Carlo (MC) simulations.
2.1.1

Molecular dynamics
Molecular dynamics calculations are widely used to study thermal stability and

folding or unfolding of proteins, to analyze the interactions between proteins and
membranes, to determine protein-ligand and protein-nucleic acid binding energies, and to
estimate various thermodynamic properties of macromolecules.154-159 In the 1950’s for
the first time Alder and Wainwright used the concept of MD to study the vibration of
atoms.160,161 McCammon et al. (1977) performed the first protein simulation.162
As mentioned earlier, MD depends on Newton’s second law of motion. The force
is calculated by taking a gradient of the potential energy (V). The potential energy is
determined using an appropriate forcefield
(2.1)
By combining Newton’s second law of motion and Eq. 2.1, we obtain

(2.2)
In an MD simulation, the initial velocities of all the atoms of a system are
randomly assigned to a Maxwell-Boltzmann distribution at a given temperature as given
in Eq. 2.3. Then, the corresponding accelerations, velocities, and positions at any time t
can be calculated by
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(2.3)

where, m = mass, v = velocity, kB = Boltzmann constant, T = temperature, and P(υ) =
probability of an atom with a velocity v.
2.1.2

Bonding and non-bonding terms
The potential energy is calculated using bonding and non-bonding terms for a

system. The bonding terms include bond length, bond angle, and torsions. Van der
Waals and electrostatic terms are considered as non-bonded interactions. The net
potential can be represented as
,
∑

(
∑
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∑
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(2.4)
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∑

(2.5)

The first term (Vbond length) is calculated by taking the square of the difference
between the bond length and its reference value. The second term (Vbond angle) is
determined by squaring the difference between the bond angle and its equilibrium value.
In the torsion expression (Vtorsion), ω is the torsional angle, Vn is the rotational barrier
height, n is the number of minimum points when the bond is rotated by 360o, and γ is the
phase factor which determines where the torsional angle passes through its minimum
value. The van der Waals term consists of attractive (r-n) and repulsive (r-m) terms,
wherein a variety of n-m terms are available (6-12, 10-12, 6-9, etc.).163,164 The most
commonly used term is a Lennard Jones 6-12 potential.165 Finally, the coulombic term
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calculates the electrostatic interaction between two charged species separated by a
distance of rij.
2.1.3

Minimization methods
The initial conformation of a biological system may not be in a local minimum.

Hence, the system must be minimized before it is equilibrated or sampled using MD
simulations. The most commonly used minimization techniques are steepest descent,166
conjugate gradient,167 and Newton-Raphson methods.168 In this study we have used
steepest descent and conjugate gradient. During the process, the coordinates of the atoms
are gradually changed. In the end the system reaches a minimum on its potential energy
surface (PES) after several iterations.
2.1.3.1

The steepest descent method
In the steepest descent method the initial configuration of a system is provided by

the user and is represented by a vector xi. At each step the gradient (gk) will be
calculated. This method is very effective if the system is located far away from a
minimum. But the convergence criterion becomes slow as the system approaches its
minimum. Therefore, often the initial iterations (user defined) will be performed using
the steepest descent algorithm followed by conjugate gradient to quickly locate minima.
2.1.3.2

The conjugate gradient method
The conjugate gradient method performs very efficiently in a narrow valley. The

gradients of successive steps are orthogonal to each other, and the directions are
conjugate. At any particular iteration, when the system moves in the direction Nk from a
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point Xk, the direction is calculated using the gradient of that point and the direction of
the previous move.
(2.6)
where γk is a constant.
2.1.4

Periodic boundary conditions
In some of the MD simulations, a macromolecule of interest will be placed inside

a box containing dimensions Lx, Ly, and Lz. Then, solvent molecules and counter ions (to
neutralize the charge of the system) will be added. The different types of simulation
boxes are cubic, truncated octahedron, hexagonal prism, rhombic dodecahedron, and
elongated dodecahedron.169 Depending upon the nature and size of a system, an
appropriate box must be chosen. In this study we have used cubic and truncated
octahedron boxes. By applying Periodic Boundary Conditions (PBC) and using a
minimum number of particles, one can efficiently sample the phase space and calculate
various properties of a system. Under PBC, the box will be replicated in all 3N
directions. The 2D arrangement of this replication is shown in Figure 2.1.
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Figure 2.1

Reimagining of a particle

Under periodic boundary conditions, when a particle drifts out of a particular box, its
image will replace it
If a particle drifts out of the central box, its image will replace it as shown in
Figure 2.1. In other words, the particle will be translated or reimaged back into the box.
This ensures that the simulation is performed with a constant number of particles. The
most expensive part of an MD simulation is calculating the non-bonded interactions
between the particles of the system. The total number of non-bonded interactions is
equal to the square of the total number of particles in a system. In priniciple, the nonbonded interactions between every pair of atoms must be calculated. However, in
practice, a non-bonded cutoff or minimum image convention is applied.170-172
In a minimum image convention, each particle sees at least one image of all other
particles of a system, and the interaction is calculated with the nearest atom or image.
When a non-bonded cutoff is applied, the non-bonded interactions between all pairs of
atoms are calculated within the cutoff region. The interactions outside the cutoff region
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are set to zero. In general, a cutoff value of 8-10 Å is recommended for calculating all
non-bonded interactions.173
2.1.5

Particle Mesh Ewald
Typically, electrostatic interactions are calculated using an Ewald summation.169

In an Ewald summation, each particle in the central box interacts with all other particles
within the box and also with the images located in all the image boxes. The location of
each image box can be linked to the central box using a vector. The vector components
are an integral multiple of the dimensions of the central box, i.e. ±iLx, ±iLy, ±iLz. The
interactions between all pairs of atoms within the central box and the interactions of each
atom (central box) with the images situated in the image boxes can be written as

∑|

|

∑

∑

.

|

|

(2.7)

The prime on the first summation in Eq. 2.7 implies that the series will not
include the interaction i = j for n = 0. The summation shown in Eq. 2.7 converges
slowly. To speed up the convergence, the summation is divided into real space and
reciprocal space. The Ewald sum in the reciprocal space was initially calculated using a
Fourier transform (FT). To perform the FT, each point charge was engulfed by a
Gaussian charge distribution of an equal magnitude using the following functional form:

( )

(

).

(2.8)

Using FT, the calculated function of the reciprocal space was not smooth enough.
Further, computing the Ewald summation is very expensive, as the algorithm scales as
N2. Therefore, Particle Mesh Ewald was introduced, where the charge density on an
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atom is distributed onto surrounding grid points.174,175 Instead of an FT, the reciprocal
space is computed using a Fast Fourier transform (FFT) to obtain a smooth function. Due
to the usage of FFT, the overall scaling of the algorithm now becomes N×lnN.
2.1.6

Ensembles
The experiments are generally performed under constant temperature, pressure,

volume, etc., and the experimental values are determined at the macroscopic level.
However, the interactions between atoms or molecules takes place at the microscopic
level. These two levels can be connected using a statistical ensemble. An ensemble is
defined as a collection of points in a phase space, representing a particular
thermodynamic state of a system.169 To mimic the experimental conditions, the MD
simulations are performed using a particular ensemble, and thereby various properties of
a system are calculated. In an MD simulation different points are generated in the phase
space as a function of time under a constant ensemble, which corresponds to various
conformations of a biological system. The different kinds of ensembles are described
below:


Microcanonical ensemble (NVE): This ensemble contains a fixed number of
particles, constant volume, and constant energy.



Canonical ensemble (NVT): This thermodynamic state is defined by a fixed
number of particles and constant volume and temperature.



Isothermal-Isobaric ensemble (NPT): This collection is characterized by a fixed
number of particles and constant pressure and temperature.
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Grand canonical ensemble (µVT): This is defined by a constant chemical
potential, volume, and temperature.
In our studies, all the MD simulations were performed under NVT or NPT

conditions. Other conditions are also possible but are not generally used.
2.1.7

Ensemble average
To determine experimental values such as pressure or heat capacity, one requires

details about the position (r) and momentum (p) of every particle in a system. Any
measured value is averaged over a particular duration of time. Therefore, an average
value of a property, determined over a period of time for an N particle system can be
written as:
(

∬

),

(2.9)

where A = observable property of a system.
In order to calculate the property of a system, an average value is replaced by an
ensemble average, wherein, numerous replicas of a system are simultaneously
considered. Hence the property can be represented as
(

∬

) (

)

(2.10)

where ρ = probability density of a system.
According to the Ergodic hypothesis, the ensemble average is equal to the time
average169
.
Under NVT conditions the probability density can be defined as
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(2.11)

(
where

= Hamiltonian,
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,

(2.12)

= Boltzmann constant, and Q = partition function.

The partition function under the canonical ensemble can be written as

∬

2.1.8

[

(

)

].

(2.13)

Integrating algorithms
In MD simulations, the time propagation of physical quantities such as positions,

velocities, accelerations, etc. are approximated using Taylor series expansions.
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(2.16)
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where r = position, υ = velocity, a = acceleration, and b = third derivative of position
with respect to time.
These quantities are calculated using procedures such as Verlet,176 Leap-frog,177
Velocity-Verlet,178 or Beeman’s algorithm.179
2.1.8.1

Verlet algorithm
The Verlet algorithm uses the positions and accelerations at time t and the

positions of previous step r (t - δt) to calculate the new positions at t + δt.
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(2.17)
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(2.18)
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Adding Eq.’s 2.17 and 2.18 we obtain
(

)

( )

(

)

( ).

(2.19)

The velocity term does not appear in this algorithm. The velocity is calculated
using

(
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)]

(2.20)

.

(2.21)

The implementation of the Verlet algorithm is straightforward, and the storage
requirements are modest. Some of the limitations of this algorithm are as follows:
a) The positions at r (t + δt) are obtained by adding a small term δt2a(t) to the
difference of two large terms (2r(t) – r(t - δt)). As a result the precision of the
positions may be lost.
b) There is no explicit term to calculate the velocities.
2.1.8.2

Leap-frog algorithm
In the leap-frog algorithm, the positions and velocities are calculated using the

following equations

(
(

)
)

( )

(

)

(2.22)

(

)

( )

(2.23)

The velocities at t+1/2δt are initially calculated. Then, the positions at t + δt are
determined in the next step. In this way, the velocities leap over the positions to give
new positions. Similarly, the positions leap over the velocities to determine new values
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of velocities. Unlike the Verlet algorithm, the leap-frog algorithm has a velocity term.
However, the velocity and the position cannot be calculated simultaneously at a particular
time t. The velocities at time t are calculated using

( )

2.1.8.3

[ (

)

(

)].

(2.24)

Velocity-Verlet algorithm
In a Velocity-Verlet algorithm the positions, velocities, and accelerations are

calculated at the same time. Initially, the positions at t + δt are calculated using

(

)

( )

( )

( )

(2.25)

The new forces are determined using current positions and then the accelerations
at t + δt are calculated. Finally, the velocities at t + δt are calculated using accerelations
at t and t + δt as shown below:
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)
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( )
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)

(2.26)

Similar to the Leap-frog algorithm, Velocity-Verlet also has an explicit term to
calculate velocities. This method is numerically stable and therefore is most widely used
in MD simulations. In this study we have used the Velocity-Verlet algorithm. A detailed
explanation of Beeman’s algorithm is provided elsewhere.169
2.1.9

Time step
There is no standard rule for choosing a time step in MD simulations. The time

step δt should be selected in such a way that it should not affect the overall dynamics of a
system. Generally, the time step should be approximately 1/10th of the shortest period of
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motion of a system. In a chemical system the bond stretches involving hydrogen will
have the highest frequencies, and the time period for C-H, O-H, and N-H bond stretches
are about 10 fs. Therefore, the most commonly used time step in MD is 1 fs.
2.1.10 Thermostat
In MD simulations various properties of a biological system are evaluated at
constant temperature. Hence, a hypothetical thermostat is used to maintain a constant
temperature throughout the simulation. The temperature of a system depends on the
average kinetic energy.

(2.27)
Some of the commonly used thermostats are
a) Berendsen thermostat
b) Langevin thermostat
c) Nosé Hoover thermostat.
2.1.10.1

Berendsen thermostat

The system is coupled to an external bath at a desired temperature.180 Then, the
velocities of all atoms of a system are scaled for a specified number of steps using a
scaling factor λ.

(

( )

)

(2.28)

where T(t) is the temperature of the system, and τ is a coupling parameter whose value
determines how loosely or tightly the system and the bath are coupled together. For a 1
fs time step, the suggested value of the coupling parameter is about 0.4 ps. The system
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can be made to fluctuate around a desired temperature using this thermostat. The
velocity scaling may cause a few artifacts. Sometimes, the temperature of the entire
system may be constant, but the temperature of the solvent might be higher than the
temperature of the solute. This leads to an unequal distribution of energy within the
system. One of the ways to overcome this problem is to implement stochastic dynamics.
These dynamics are based on a Langevin equation of motion.
2.1.10.2

Langevin thermostat

For a Langevin thermostat, each particle behaves as if it is immersed in a bath of
viscous medium.181 The Langevin equation of motion is used instead of Newton’s
second law of motion. The Langevin equation of motion for a particle is given as
( )

( )

( )

(2.29)

The term F is the force acting on a particle, and the second term is the motion of a
particle in the solvent medium, generally known as frictional drag due to the solvent.
The frictional force on a particle is given by
(2.30)
where ξ is the frictional coefficient, which is directly related to the collision frequency γ,
and γ = ξ/m (m = mass of the particle). The third term represents the random fluctuations
caused by the interaction of a particle with the solvent molecules. R(t) is proportional to
(2kB(T*m))1/2. R(t) and γ are adjusted to maintain the desired temperature.
The advantages of the Langevin thermostat are 1) the canonical ensemble can be
effectively sampled. 2) Each particle will be in contact with a local bath. 3) Due to the
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presence of R(t), it is possible to take larger time steps. In this study, we have used the
Langevin thermostat. A detailed explanation of the Nosé Hoover thermostat is described
elsewhere.182
2.1.11 Barostat
The simulations can also be performed under constant pressure. The system will
be maintained under constant pressure by varying the volume of the simulation box. The
volume fluctuation depends on the isothermal compressibility.

( ) .

(2.31)

The volume of a simulation box is scaled by a factor of λ, which is equivalent to
scaling the atomic coordinates by λ1/3.

(

)

(2.32)

where δt = time step, τp = coupling constant, P = pressure of the system, and Pbath =
pressure of the bath. The new positions are given as
,
where
2.2

are the new positions and

(2.33)

are the current positions.

Free energy calculations
Among all the thermodynamic properties, the most important is the change in free

energy. When a system is simulated under the canonical ensemble, the Helmholtz free
energy can be determined. Under NPT conditions, the Gibbs free energy can be
calculated. Traditional MD or MC simulations do not efficiently sample the whole phase
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space of a system. Hence, the free energy values derived using these methods will have
large errors.
Usually, the system of interest will be initially sampled using MC or MD
simulations. Then, free energy perturbation (FEP) or thermodynamic integration (TI)
methods are used to calculate free energy changes.183,184 We have used thermodynamic
integration to determine protein-ligand free energy of binding. A detailed description of
FEP is provided elsewhere.169
2.2.1

Thermodynamic integration
Thermodynamic integration (TI) is one of the most accurate methods for

calculating the free energy of binding. The change in free energy is determined by

〈 〉

∫

.

(2.34)

∆A is determined by calculating an ensemble average of the derivative of potential energy
with respect to λ, where λ is a perturbing parameter. At λ=0, the receptor and ligand will
have 100% interaction, and at λ=1 they will have no interaction. The ∆A value is
calculated by considering a series of λ values between 0 and 1. At each λ value the
system must be properly equilibrated. The integral value given in Eq. 2.34 is calculated
numerically. The derivation of the above expression is shown below.
The Helmholtz free energy at any λ value is represented as
( )

( )

(2.35)

If λ is varied from 0 and 1, then the change in free energy is given by

∫

( )
( )
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(2.36)

The partition coefficient Q under NVT conditions is

∬

(

[

)

]

(2.37)

Therefore, ∂Q/∂λ can be written as
(

∬

)

(

[

)

]

(2.38)

Substituting Eq. 2.37 and Eq.2.38 into Eq. 2.36 gives

(

∬

)

∫
(

∬

(

(
(

)

)

)

(2.39)

)

By applying the Ergodic hypothesis, Eq. 2.39 becomes

∫ 〈 〉

,

(2.40)

where < >λ is an ensemble average with respect to λ. The Hamiltonian can be written as
( )

( )

(2.41)

Under NVT conditions the ensemble average of the kinetic energy is constant and
can be ignored. Therefore, the ensemble average of the Hamiltonian is equal to the
ensemble average of the potential energy, and hence Eq. 2.40 becomes

∫ 〈 〉

(2.42)

The integrand of the above expression is determined using numerical integration. Thus,
∆A can also be written as
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∑

〈 〉,

(2.43)

where the wi’s are the weights.
The potential energy is calculated using a mixed potential function as shown
below
( )

(

)

[

(

)]

,

(2.44)

where V0 is the potential of the unperturbed Hamiltonian, V1 is the potential of the
perturbed Hamiltonian, and k is a value between 1 and 6.
In a TI calculation, the electrostatic interactions and then the van der Waals
interactions of a ligand with the active site residues of a protein are eliminated by varying
λ between 0 and 1. The partial atomic charges of the atoms of a ligand are made to zero
to eliminate the electrostatic interactions, and in a separate calculation the ε (interaction
strength) term in the Lennard-Jones potential becomes zero to remove the van der Waals
interactions. When a linear-mixing potential function is used, i.e. k =1, the integrand in
Eq. 2.42 diverges at λ =1 when removing the van der Waals interactions.185 At λ = 1, ε
becomes zero, and hence the van der Waals potential also becomes zero. However, near
λ = 1, ε is close to zero, but not exactly zero. Then, if the distance between two atoms
approaches zero, the van der Waals term in the potential energy of the system approaches
infinity. Hence, when a linear-mixing potential function is used, special numerical
integration methods must be applied in order to achieve a better estimate of the integral.
As long as k ≥ 4, the integral becomes finite as λ→1, but a better estimate of the free
energy is obtained by using k = 6.185
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2.2.2

Implicit solvent models
The free energy of binding determined using FEP or TI is time consuming and

expensive.186 Typically, both these methods estimate the free energy changes using an
explicit solvent simulation. In an explicit solvent model, the solute will be surrounded by
thousands of solvent molecules. Hence, most of the computational time is spent in
calculating solvent-solvent and solute-solvent interactions. However, if the explicit
solvent molecules can be replaced by an infinite solvent continuum medium with a
specific dielectric constant, then more time can be dedicated to sample the solute
particles. The solvent continuum model is commonly known as the implicit solvent
model.
The free energy of binding for a protein-ligand system can be expressed as
,

(2.45)

where ∆Eforcefield is the internal energy of a system in the gas phase.
(2.46)
Similarly, ∆Gsol is calculated using the following relationship
(2.47)
∆Gelec is an electrostatic term and the last two terms are non-polar contributions. The
solvent molecules have to reorganize and create a cavity when a solute is added to a pure
solvent. Therefore, the entropy of the solvent decreases, and the term ∆Gcavity will be
positive. Various methods have been proposed for calculating ∆Gelec. The most widely
used methods are Poisson-Boltzmann and Generalized Born. The T∆S values were
calculated by performing normal mode analyses.
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2.2.2.1

Poisson-Boltzmann
The linearized form of the Poisson-Boltzmann equation can be written as187
[ ( )

( )]

[ ( )]

( )

(2.48)

where ϕ(r) is the electrostatic potential, ρ(r) is the charge density, and ε(r) is the dielectric
constant of the medium, and

can be calculated using the Debye-Hückel inverse length

and is given by

(2.49)
where e = charge, I = ionic strength of the solution, and NA = Avogadro’s number.
The Poisson-Boltzmann equation is solved numerically using a finite-difference
method.188,189 The electrostatic interactions are calculated using grid points. The solute
is assigned a dielectric constant of 1, 2, or 4, and the solvent, usually water, is assigned a
dielectric constant of 80. The grid points belonging to the solute and the solvent can be
distinguished by estimating the solvent accessible surface area. Thus, a unique dielectric
constant will be allocated to the grid points belonging to solute or solvent areas.
2.2.2.2

Generalized Born
Solving the Poisson-Boltzmann equation using numerical integration is time

consuming, memory intensive, and computationally expensive.190 Therefore, an
alternative approach for calculating ∆Gelec is using the Generalized Born equation.191,192
The Generalized Born model is computationally inexpensive and can be calculated much
faster than the Poisson-Boltzmann method.
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In a Generalized Born equation, each atom of a system is represented by a sphere
of radius ri and charge qi. The spherical particle is assumed to be filled with uniform
matter and has a dielectric constant ranging from 1-4, and the surrounding solvent
medium contains a dielectric constant of 80.193 The interactions between each pair of
atoms is calculated, and the net electrostatic interactions of a system is defined as

(

)∑

∑

(

)

.

(2.50)

The function f depends on rij and the Born radii aij and is given by

(

)

√(

),

(2.51)

where rij is the distance between the atoms i and j, aij = (aiaj)1/2, ai and aj are known as
effective Born radii, and D = r2ij/(2aij)2.
2.2.2.3

Non polar contribution
Apart from the electrostatic contribution, ∆Gsol also depends on the van der Waals

and cavity terms as shown below
,

(2.52)

where γ and b are constants and SASA is the solvent accessible surface area.
During cavity formation the solvent molecules in the first solvation shell are
affected the most. Similarly, the van der Waals interactions between the solute and
solvent molecules mainly occur in the first solvation shell, too. Therefore, the van der
Waals and cavity terms are combined.194,195 Usually, a probe of radius 1.4 Å will be
made to roll along the van der Waals surface of the solute to calculate the SASA.196,197
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2.2.2.4

Normal mode analysis
Biological systems (i.e. proteins) may exist in more than one conformation.198,199

The tertiary structure of a protein will change during a conformational change. Similarly,
the protein will undergo structural changes upon the binding of small, drug-like
molecules.200 These changes occur on the order of micro or milliseconds.201 Therefore,
longer MD simulations must be performed for observing such changes. However,
carrying out such simulations is computationally expensive and time consuming.201,202
Alternatively, these changes can be analyzed by conducting a normal mode analysis.203
The potential energy of a system is calculated using a defined forcefield. Then,
the system will be minimized to a local minimum. Later, a 3N×3N Hessian matrix is
constructed. Further, the Hessian matrix will be converted into a force constant matrix
using the following relationship.
,

(2.53)

where M is a diagonal matrix and contains the masses of the atoms and V" is the Hessian
matrix.
The F matrix is diagonalized, determining its eigenvalues and eigenvectors.
Finally, the frequencies corresponding to each normal mode are calculated using the
eigenvalues.

√

.

Thermodynamic properties such as internal energy, enthalpy, and entropy can be
calculated using a normal mode analysis. The net entropy can be represented as
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(2.54)

.

(2.55)

The vibrational entropy term plays an important role when determining the free
energy of binding. The vibrational entropy is given by

∑

[

(
(

)],

(2.56)

)

where νi is the frequency.
The low frequency modes are important as they correspond to large scale motions
of proteins.204,205 Therefore, the contribution of vibrational entropy from these modes
will influence the net entropy of a system.
2.3

Docking studies
Docking studies are mainly used for analyzing protein-protein, protein-ligand, and

protein-nucleotide binding interactions.206-208 In protein-ligand molecular docking, the
orientation and conformation of a ligand in the active site are determined.209 Similarly,
the interactions between the ligand and the active site residues are analyzed, and their
corresponding binding energies are calculated.210,211 Another important part of docking
studies is virtual screening. Using a virtual screening process, thousands of small
molecules are screened to identify a set of ligands which can effectively bind to a protein
of interest.212,213 This technique helps to engineer new lead molecules in the drug-design
field. Over the last decade the computational accuracy, performance, and speed of many
docking programs have increased tremendously.214-216 The predicted protein-ligand
binding modes and affinities values can be within experimental errors.216,217
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Sampling and scoring are the two major steps in docking studies. In the sampling
section, ligand sampling and protein flexibility plays a major role.218 During the docking
studies, hundreds or thousands of ligand poses will be generated. The orientation,
interaction, and binding of each pose in the active site will be examined. Using a scoring
function, all conformers will be ranked based on their binding energies in order to
identify a best conformer.210,219 Therefore, a scoring function is a crucial component in
identifying the lowest energy conformer and binding mode of a ligand. There exists a
variety of sampling techniques and scoring functions, some of which are briefly
explained in the following section.
2.3.1

Sampling techniques
When a ligand binds to a protein, the active site residues will often rearrange to

accommodate the ligand. As a result, the conformation of the entire protein or the sidechain conformation of an amino acid may change.218,220 During protein-ligand docking
studies, the protein can be made flexible. However, from a computational stand point,
the entire protein cannot be made flexible due to the size of a protein and its numerous
degrees of freedom. Therefore, various approaches have been proposed to tackle protein
flexibility. Some of them are discussed below.
2.3.1.1

Soft docking
In this method the protein and ligand structures are allowed to change only to

some extent. Both structures are represented as smooth molecular surfaces.221.222 The
molecular surface of the ligand is translated and rotated in different ways to align with
the active site surface. The overlapped volume during the interactions is subtracted to
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avoid van der Waals repulsions. However, various ligand conformations are not
completely explored. This method is simple and computationally efficient, but the
binding modes and affinities are not accurate and reliable.
2.3.1.2

Rigid docking
In this approach, the backbone and the side chains of the protein are made rigid.

The analysis is done using a single conformation of the protein.223,224 During the process,
the ligand is made flexible, and various conformers of the ligand are considered. Finally,
an optimal binding pose and a lowest energy conformer of a ligand will be detected. This
method is computationally fast and inexpensive. Due to the rigidity of the protein, when
a ligand binds to the active site, it may overlap or sterically clash with the active site
residues. In order to obtain reliable binding poses, the system can be minimized.
2.3.1.3

Side-chain flexibility
In this approach, the side chains of a protein are made flexible, and the backbone

atoms are made rigid. The conformation of side chains are changed using a rotamer
library.225,226 A rotamer library mainly consists of experimentally observed side-chain
conformers of various amino acids.225 Depending upon the interaction between a ligand
and the active site residues, the side-chain conformation of an amino acid located in the
active site or in any other site will be changed. This treatment allows for the exploration
of the conformational phase space of a protein in the presence of a ligand. One of the
advantages of this method is that a lower energy conformer of a protein can be obtained
when compared to the methods discussed above.
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2.3.1.4

Multiple protein structure docking
The most efficient way to incorporate protein flexibility is to consider an

ensemble of various protein structures.227-229 A few similar regions from a selected set of
proteins structures will be identified to construct the flexible binding site of a protein of
interest.230 The similar regions are merged together, and the dissimilar regions are used
to create new conformers of a protein. In another approach the protein of interest is
divided into a rigid part and several flexible parts according to the protein structures
present in the ensemble.231 Depending upon the displacement or orientation of the
ligand, for each flexible part a particular conformer will be selected. Then, all the
selected conformers will be attached to the rigid part of the protein. This procedure helps
to construct a protein-ligand structure. This method scales linearly and efficiently
predicts the protein-ligand binding modes and affinities.
Another way to attain protein flexibility is to consider an experimentally
determined protein structure and run a short MD simulation. Then, generate a few
snapshots of the protein from the last few nanoseconds of the sampling process. The
ligand will then be docked to all generated snapshots. In this way, we can dock the
ligand to different conformers of the protein. Finally, the interactions between the ligand
and the active site residues in all snapshots will be analyzed, and the best binding mode
and affinity will be selected.
2.3.2

Ligand sampling
The most important aspect of molecular docking is ligand sampling. The

following methods are commonly used.
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2.3.2.1

Systematic search
This method explores all possible binding poses and also all degrees of freedom

of a ligand in the active site. The basic approach is to systematically rotate each rotatable
bond in order to analyze various conformers of a ligand.232 In a given system, as the
number of rotatable bonds increases, the complexity of the algorithm increases
exponentially. However, this method can be applicable if the molecule has a small
number of rotatable bonds.
2.3.2.2

Random search
Random search algorithms are also known as stochastic algorithms, wherein the

orientation and conformation of a ligand are randomly changed to explore the ligand’s
conformational phase space. The most commonly used algorithms are Monte Carlo233,234
and genetic algorithms.235,236
2.3.2.2.1

Monte Carlo

In a Monte Carlo algorithm the following are the steps involved:
a) Using a random number generator, the current conformation of a ligand will
be randomly changed, and a new conformer will be produced.
b) The energy of the new conformer will be determined.
c) If the energy of the new conformer is less than the energy of the previous one,
then the new conformer will be taken as the current conformer for the next
iteration.
d) If the energy of the new conformer is higher than the energy of the previous
conformer, then a Boltzmann factor based on the energy difference will be
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calculated. A random number between 0 and 1 will be generated, and if the
Boltzmann factor is greater than the random number, then the new conformer
will be accepted.
Various conformations of a ligand are randomly generated and are accepted based
on the above procedure. This process is repeated for several hundreds to thousands of
iterations (user defined). Further, a few of the lowest energy conformers are selected.
The corresponding binding affinities are calculated and ranked according to their energy
values.
2.3.2.2.2

Genetic algorithm

An initial population of various conformers of a ligand must be generated. The
generated conformers will be categorized into different groups, depending upon their
orientation and interactions with the active site. Within the same group, the bond lengths,
bond angles, and dihedral angles are randomly changed, which is commonly known as a
mutation. Further, a side chain or a part of a ligand is exchanged among any two selected
conformers, i.e. crossover.
Additionally, a complete conformer or a part of a conformer will be exchanged
among various groups, which is known as a migration. In each group, each conformer
will be translated and rotated. At the end of every iteration, the favorable conformers are
selected, optimized, and ranked using a scoring function. Then, the lowest energy
conformer is chosen and taken as an initial structure for next iteration. Based on the
results of the previous iteration, the mutations, crossovers, and migration processes are
adjusted in the present iteration to obtain a better structure than the previous step. In this
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way, a rigorous ligand search will be performed for user defined iterations, and the
selected ligands will be ranked based on a scoring function. This is an efficient method
for identifying a suitable conformer of a ligand when it binds into the active site of a
protein.
2.3.3

Scoring function
The scoring function is an important step in molecular docking studies. An

efficient scoring function should be capable of calculating the energies of various
conformers of a ligand, rank them, and select a best conformer. Most of the docking
programs use simple scoring functions that are computationally fast and effective. Some
of the docking programs are missing the entropic effects when a ligand binds into the
active site of a protein.237 A number of scoring functions have been developed, which are
mainly divided into the following categories.
2.3.3.1

Forcefield scoring function
The binding energy of a ligand can be calculated using molecular mechanics

forcefields.238,239 The internal terms of the ligands (bond lengths, bond angles, and
torsions) and the non-bonded terms are calculated. The van der Waals interactions are
calculated using a Lennard-Jones potential, and the electrostatic interactions are
calculated using Coulombs law. To decrease the computational cost, the solvent effects
are included using solvent continuum models with a constant dielectric constant.
Determining the entropic contribution to the binding energy is a major challenge in this
field.
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2.3.3.2

Empirical scoring function
The binding energy of various ligand conformers is calculated as sum of van der

Waals, electrostatics, hydrogen bonding, desolvation, and hydrophobicity and is
represented as
∑

(2.57)

The coefficients, wi, are determined by performing a regression analysis on a training set
containing a variety of experimentally known protein-ligand binding energies.240 The
empirical scoring function is much simpler than forcefield scoring. However, the validity
of the weighing terms and the regression analysis primarily depends upon the training set.
2.3.3.3

Knowledge-based scoring function
The crystal structures of relatively similar protein-ligand systems will be

considered as a training set.241-243 This scoring function mainly relies on the structural
information of the training set, rather than binding energies. In each protein-ligand
system, the atomic pair interaction potential is calculated using an empirical method244
and is given as

( )

[

( )
( )

]

(2.58)

where ρ(r) is the density of the protein-ligand atom pair at the distance r and ρ(r)* is a
reference state. In the reference state, two atoms of an atomic pair do not interact with
each other. The ligand binding energy is calculated by combining the interaction
potential of all protein-ligand systems of the training set. The ligand binding potential is
calculated using a large set of experimentally known protein-ligand structures.
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Therefore, this scoring function can be more accurate than forcefield and empirical
scoring functions.
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CHAPTER III
BINDING FREE ENERGIES OF OXIMES CALCULATED USING
THERMODYNAMIC INTEGRATION

The main aim of this study was to calculate the oxime free energy of binding in
human AChE (hAChE) and human BChE (hBChE) inhibited by nerve agents. We were
also interested to calculate the oxime free energy of binding in uninhibited hAChE and
hBChE. The nerve agents sarin and tabun and the reactivators 2-PAM, MMB-4, HI-6,
and obidoxime were considered. In this chapter the interactions of oximes with various
active site residues in all inhibited and uninhibited systems of hAChE and hBChE are
discussed. The outcomes of TI calculations and a comparison with available
experimental values are also reported.
3.1
3.1.1

Computational methods
Cholinesterases models
The crystal structures of hAChE (PDB code: 1F8U)245 and hBChE (PDB code:

1P0I)246 were imported from the PDB server.247 The enzymes hAChE and hBChE
consists of 539 and 529 residues respectively. The missing residues of hAChE (1-12)
and hBChE (1-3, 378, 379, and 455) were modeled and placed in their respective
locations using Spartan’06. In both enzymes the cysteine residues were connected
through S-S bonds. Using xleap, the S-S bonds between the residues 65 and 92, 253 and
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268, and 405 and 525 in hAChE and between 65 and 92, 252 and 263, and 400 and 519 in
hBChE were connected. Then, the modified protein structures were simulated using an
implicit solvent model. The systems were initially minimized for 1000 steps, heated (10300K) for 100 ps, and then equilibrated for 1 ns using Amber8248 and the ff99
forcefield249 with a 16 Å cutoff. The equilibrated structures were submitted to the H++
server,250,251 to obtain the protonation states of the titratable residues and the total charge
of the protein.
3.1.2

Modeling of inhibited cholinesterases and reactivators
The sarin-serine and tabun-serine models were built using Spartan’06. The

leaving groups, –F and –CN in sarin and tabun were removed from the models.
Conformational analysis was done using AM1,252 and the lowest energy conformer was
chosen. A geometry optimization was done with Hartree-Fock (HF) and the 6-31G*
basis set using Q-Chem 3.2.151 In the ff99 forcefield, the partial atomic charges of the
amino acids atoms are derived using HF/6-31G*. Hence, to maintain consistency with
the forcefield, the optimization was done using HF/6-31G*. Further, the partial atomic
charges for sarin-serine and tabun-serine were derived using the restrained electrostatic
potential approach.253
The active serine in hAChE (S199) and hBChE (S198) were removed and
replaced with the optimized sarin-serine and tabun-serine (OP-serine) structures. In this
way, four different inhibited enzymes, hAChE-sarin, hAChE-tabun, hBChE-sarin, and
hBChE-tabun were constructed. Then, all the inhibited systems were equilibrated using a
similar procedure as mentioned above.
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The oximes 2-PAM, MMB-4, HI-6, and obidoxime were also built using
Spartan’06. Their conformational analyses, geometry optimization, and partial atomic
charges were calculated using a similar procedure to that described earlier.
3.1.3

Docking studies
All the docking studies were performed with the Lamarckian genetic algorithm236

using Autodock4.254 2-PAM, MMB-4, HI-6, and obidoxime were individually docked to
all inhibited and uninhibited systems. In the inhibited systems, the OP-serine complex
was made flexible, while the remaining part of the protein was treated as rigid. Similarly,
the active site serine was considered as flexible in the uninhibited enzymes. Various
conformers of the reactivator were visualized using VMD.255 In the inhibited systems a
particular conformer of the reactivator was selected based on the following criteria. The
O-H (on the oxime group) of the reactivator and P of the OP-serine should align along the
same axis. Secondly, a conformer of the reactivator with the shortest distance between
O-H of the reactivator and P of the OP-serine was selected. In case of uninhibited
systems, a conformer of the reactivator which was closest to the active site serine was
chosen. The interactions of the selected conformers of the reactivators with all inhibited
and uninhibited systems were verified by performing MD simulations.
3.1.4

Molecular dynamics simulations
Explicit solvent MD simulations were performed using Amber 8 and the ff99

forcefield. Amber’s general atomic forcefield (gaff)256 was used for the reactivators
(ligands). Using xleap, the inhibited and uninhibited systems were taken in a truncated
octahedron box and solvated with TIP3P257 water molecules. The inhibited and the
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uninhibited hAChE systems were neutralized with 5 Na+ ions. hBChE was neutralized
with 2 Cl- ions. The minimization, heating, equilibration, and sampling were performed
using the sander module of Amber8. Initial minimization was done for 1000 steps with a
force constant restraint of 500 kcal/mol/Å2 on the enzyme and the reactivator. Then, the
whole system was minimized for 2500 steps. The system was heated for 100 ps from 10
K to 300 K under NVT conditions with a restraint of 10 kcal/mol/Å2 on the protein and
the reactivator. Next, it was equilibrated for 900 ps at 300 K under NPT conditions.
Under NVT conditions, the system was sampled for 10 ns. During the equilibration and
sampling process, the hydrogens were constrained using the SHAKE algorithm,258,259 and
a constant temperature was maintained using Langevin dynamics with a collision
frequency of 1.0 ps-1.181 The electrostatic interactions were handled using Particle Mesh
Ewald (PME)260-262 under periodic boundary conditions with an 8 Å cutoff. All the
dynamics were performed with a time step of 2 fs.
3.1.5

Thermodynamic integration
The TI calculations were performed using eight different λ values (0.02544,

0.12923, 0.29707, 0.5, 0.70292, 0.87076, 0.97455, 1.0), k = 6, and NVT conditions. The
simulations were performed using a 1 fs time step. Each system was sampled on an
average of 10-20 ns for each λ value. The coordinates and the velocities at the end of the
explicit solvent sampling process were used as initial inputs.
The free energy of binding was calculated in two steps. Initially, the electrostatic
and later the van der Waals interactions between protein and ligand were removed.
These interactions are gradually eliminated by perturbing the system using the λ
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parameter, which controls the interaction between the receptor and the ligand. The
electrostatic and van der Waals calculations were separately simulated.
The chemical process between an inhibited or uninhibited system and an oxime
during the TI calculations can be represented as
(

)

(

)

(

)

(3.1)

where enzyme (aq) = inhibited/uninhibited system, oxime (aq) = oxime, complex (aq) =
inhibited/uninhibited system + oxime, and ∆ATI = binding free energy.
The above process takes place in two steps:
(
(

)
)

(

)

( )

(

( )

(

)
)

(3.2)
(3.3)

In the first step the complex gets dissociated into enzyme (aq) and oxime (g). During this
process the interactions between the oxime and the active site residues gradually decrease
and the aqueous phase oxime vanishes from the active site and appears in the gas phase.
In order to complete the thermodynamic cycle, the reactivator has to reappear in solution
somewhere else. Therefore, the oxime was separately taken in a truncated octahedron
box along with explicit water molecules (step 2). They were minimized, heated,
equilibrated, and sampled for 10 ns using a similar procedure as mentioned earlier. Later,
the TI simulations for the oxime by itself were performed. The net free energy of binding
from step 1 and step 2 can be written as
.
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(3.4)

3.2
3.2.1

Results and discussion
Explicit solvent simulations
The protein-ligand interactions are largely influenced by the solvent. In MD

simulations, the solute-solvent and solvent-solvent interactions can be considered by
performing explicit solvent simulations. All the inhibited and uninhibited systems were
sampled for 10 ns. The stability of the systems was verified by plotting RMSd vs. time
graphs. The RMSd vs. time plot of all the inhibited and uninhibited systems of 2-PAM,
MMB-4, HI-6, and obidoxime are shown in Figures 3.1, 3.2, 3.3, and 3.4.

Figure 3.1

RMSd vs. time plots of inhibited and uninhibited systems with 2-PAM
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Figure 3.2

RMSd vs. time plots of inhibited and uninhibited systems with MMB-4

Figure 3.3

RMSd vs. time plots of inhibited and uninhibited systems with HI-6
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Figure 3.4

RMSd vs. time plots of inhibited and uninhibited systems with obidoxime

During the explicit solvent simulations, the reactivator was expected to exhibit
hydrogen bonding, electrostatic interactions, or π-π stacking with the active site residues.
Using ptraj, hydrogen bonds between the reactivator and the active site residues were
analyzed. For this process, the last 5 ns of the sampling process were considered. The
hydrogen bond analysis of 2-PAM, MMB-4, HI-6, and obidoxime are shown in Table
3.1. The atom labels on MMB-4, HI-6, and obidoxime as tabulated in Table 3.1 are
shown in Figure 3.5.
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Table 3.1

Hydrogen bonding analysis of inhibited and uninhibited systems of 2-PAM,
MMB-4, HI-6, and obidoxime.

System

Donor

Acceptor H

Acceptor

hAChE-tabun-2-PAM
hAChE-2-PAM
hBChE-sarin-2-PAM
hBChE-tabun-2-PAM
hBChE-2-PAM
hAChE-sarin-MMB-4

ASP70@OD
GLU448@OE
GLU325@O
ALA328@O
GLU441@OE
GLU198@OE
GLU80@OE
GLU448@OE
GLU448@OE
GLU80@OE
MMB4@O'
ASP127@OD
GLU80@OE
HIS438@O
HI6@O'
GLU80@OE
GLU448@OE
GLU80@OE
GLU443@OE
OBD@O'
GLU197@OE
GLU443@OE

2-PAM@H
2-PAM@H
2-PAM@H
2-PAM@H
2-PAM@H
MMB-4@H'
MMB-4@H"
MMB-4@H'
MMB-4@H'
MMB-4@H"
GLY115@H
HI-6@N'H"
HI-6@N'H"
HI-6@N'H'
HIS126@HE
HI-6@N'H"
OBD@H'
OBD@H'
OBD@H"
GLY117@H
OBD@H'
OBD@H"

2-PAM@O
2-PAM@O
2-PAM@O
2-PAM@O
2-PAM@O
MMB-4@O'
MMB-4@O"
MMB-4@O'
MMB-4@O'
MMB-4@O"
GLY115@N
HI-6@N'
HI-6@N'
HI-6@N'
HIS126@NE2
HI-6@N'
OBD@O'
OBD@O'
OBD@O"
GLY117@N
OBD@O'
OBD@O"

hAChE-tabun-MMB-4
hAChE-MMB-4
hBChE-MMB-4
hAChE-sarin-HI-6
hAChE-tabun-HI-6
hBChE-sarin-HI-6
hBChE-tabun-HI-6
hBChE-HI-6
hAChE-tabun-obidoxime
hAChE-obidoxime
hBChE-tabun-obidoxime
hBChE-obidoxime

Occupation
(%)
9.08
91.19
4.38
41.20
30.10
80.78
79.96
58.92
34.66
63.90
13.06
5.00
11.40
31.64
4.08
46.81
100
36.14
100
98.64
75.96
50.92

Where OD = oxygen at δ position, OE = oxygen at ε position, HE = hydrogen at ε
position, and OBD = obidoxime.

Figure 3.5

Structures of 1) 2-PAM, 2) MMB-4, 3) HI-6, and 4) obidoxime
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2-PAM displayed highest percentage of hydrogen bond interaction with Glu448 in
hAChE-2-PAM among all the inhibited and uninhibited systems of 2-PAM, a moderate
percentage of interactions with Glu441 in hBChE-2-PAM, and with Ala328 in hBChEtabun-2PAM. In addition, 2-PAM has exhibited a low percentage of interaction with
Asp70 in hAChE-tabun-2-PAM and with Glu325 in hBChE-sarin-2-PAM systems. 2PAM did not display hydrogen bond interactions in hAChE-sarin-2-PAM.
MMB-4 did not exhibit hydrogen bonding in hBChE-sarin-MMB-4 and hBChEtabun-MMB-4. Similarly, obidoxime did not display hydrogen bonding with the active
site residues in hAChE-sarin-obidoxime and hBChE-sarin-obidoxime systems. However,
MMB-4 has shown interactions with Glu80 and Glu198 in hAChE-sarin-MMB-4 and
with Glu80 in hBChE-MMB-4 system. Among all the reactivators, only obidoxime has
shown a 100% hydrogen bond interaction throughout the 5 ns of simulation with Glu448
in hAChE-tabun-obidoxime and with Glu443 in hBChE-tabun-obidoxime.
HI-6 exhibited hydrogen bonding in hAChE-sarin-HI-6, hAChE-tabun-HI-6, and
hBChE-tabun-HI-6, and no hydrogen bond formation in hAChE-HI-6. MMB-4 and
obidoxime have shown higher percentages of hydrogen bond interaction with various
active site residues compared to 2-PAM and HI-6. Glu80 was a common residue which
has shown hydrogen bonding interactions with MMB-4, HI-6, and obidoxime.
The reactivators have also displayed π-π interactions with various active site
residues. 2-PAM exhibited π-π interactions with Tyr333 and Tyr73 in hAChE-sarin-2PAM, as shown in Figure 3.6, and with Trp282 in hAChE-tabun-2-PAM. In hAChEtabun-MMB-4, MMB-4 displayed a π-π interaction with Tyr333 as shown in Figure 3.7.
Similarly, MMB-4 also exhibited π-π interactions with Tyr332 in hBChE-sarin-MMB-4
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and with Tyr129 in hAChE-MMB-4. HI-6 displayed π-π interactions with Tyr332 and
Tyr440 in hBChE-sarin-HI-6 as shown in Figure 3.8. Obidoxime did not show any π-π
interactions.

Figure 3.6

2-PAM displaying π-π stacking with Tyr73 and Tyr333 in hAChE-sarin-2PAM
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Figure 3.7

MMB-4 displaying π-π stacking with Tyr333 in hAChE-tabun-MMB-4

Figure 3.8

HI-6 displaying π- π stacking with Tyr332 and Tyr440 in hBChE-sarin-HI6
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3.2.2

Thermodynamic integration
TI calculations were performed for all the inhibited and uninhibited systems of

MMB-4 and obidoxime. For each λ value, the simulation was run until it converged. ∆A
was obtained by multiplying the dV/dλ term for each λ value with the standard weights
provided in the Amber manual. A detailed explanation for calculating ΔA is provided in
the Amber tutorial.263 To verify convergence, dV/dλ vs. λ graphs were plotted. The
dV/dλ vs. λ plots of the electrostatic and van der Waals simulations for all MMB-4
systems are shown in Figures 3.9 and 3.10. Similarly, the corresponding plots of all
obidoxime systems are shown in Figures 3.11 and 3.12. The systems simulated with
0.02544, 0.12923, 0.29707, 0.5, 0.70292, and 0.87076 λ values on average took 20 ns for
convergence, whereas for λ = 0.9707 and 1 they took 8-10 ns to converge. The
individual electrostatic and van der Waals contribution and their combined energy values
for all MMB-4 and obidoxime systems are tabulated in Table 3.2. The free energy of
binding was calculated using Eq. 3.4.
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Figure 3.9

dV/dλ vs. λ plot for the electrostatic simulation of the inhibited and
uninhibited systems of MMB-4

Figure 3.10

dV/dλ vs. λ plot for the van der Waals simulation of the inhibited and
uninhibited systems of MMB-4
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Figure 3.11

dV/dλ vs. λ plot for the electrostatic simulation of the inhibited and
uninhibited systems of obidoxime

Figure 3.12

dV/dλ vs. λ plot for the van der Waals simulation for the inhibited and
uninhibited systems of obidoxime
61

Table 3.2

Electrostatic, van der Waals, and total energies of inhibited and uninhibited
systems of MMB-4 and obidoxime (kcal/mol).

System
hAChE-sarin-MMB-4
hAChE-tabun-MMB-4
hAChE-MMB-4
hBChE-sarin-MMB-4
hBChE-tabun-MMB-4
hBChE-MMB-4
hAChE-sarin-obidoxime
hAChE-tabun-obidoxime
hAChE-obidoxime
hBChE-sarin-obidoxime
hBChE-tabun-obidoxime
hBChE-obidoxime
MMB-4
Obidoxime

Electrostatics
-5.3
-9.0
-6.4
-6.1
-2.6
-6.2
-13.9
-12.8
-14.8
-13.0
-10.7
-12.6
-10.2
-18.4

Van der Waals
-8.2
-8.0
-8.8
-8.4
-4.7
-9.6
-12.3
-9.3
-11.7
-4.7
-10.6
-8.6
-12.6
-13.3

Total
-13.5
-17.0
-15.2
-14.5
-7.3
-15.8
-26.2
-22.1
-26.5
-17.7
-21.3
-21.2
-22.8
-31.7

The calculated binding free energy values were compared with the available
experiments. The dissociation constant values (Kd) of oxime reactivation for all the
inhibited systems of MMB-4 and obidoxime (except hBChE-tabun-MMB-4) were
obtained from the literature.264-267 While comparing the computational values with the
experimental free energies, both must be converted to standard free energies. The
experimental Kd values are usually expressed in µM concentration, even though
equilibrium constants are unitless. Therefore, the experimental Kd (in µM) values were
made unitless, and ∆G0 (dissociation) was calculated using -RTln(Kd). The binding
∆G0exp value was obtained by taking -∆G0 of dissociation.
In an MD calculation the effective concentration is not 1 M. Therefore, in case of
the TI results, while converting the free energy value to a standard free energy, an extra
term must be added to Eq. 3.4. If the simulation box sizes of complex, receptor, and
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ligand were the same size during the TI calculation, then the following correction is
valid.268,269

( ),

(3.5)

where V is the volume of the simulated complex box and Vo is the volume occupied by
one ligand (1661 Å3) at a concentration of 1 M.
During the TI calculations a larger box was used for the complex and receptor
than for the oxime (the complex and receptor box sizes are equal). Since the free energy
is path independent, we have assumed that the complex and receptor will transform from
large boxes to standard boxes containing a volume of Vo, and the oxime from a small box
to a standard box, too. The following correction was derived in order to obtain the
standard free energy term by modifying the chemical steps 3.2 and 3.3:
(

)

(

)

( )

( )

( )

(3.6)
(3.7)

Since the volume of the complex and receptor solvated boxes are equal, i.e. Vc = Vr;
therefore
(3.8)
Similarly,
(

)

( )

(3.9)
( ),

where Vs is the volume of the reactivator solvated box.
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(3.10)

Combining Eq.’s 3.8 and 3.10, the standard free energy of binding can be written as
(3.11)
Therefore,

( )

(3.12)

According to Eq. 3.4, ∆ATI = ∆Aoxime, TI - ∆Acomplex, TI, and hence Eq. 3.12 can be written as

( )

(3.13)

∆ATI, RTln(Vo/Vs), ∆Ao, ∆G0exp, and the difference between ∆A0 and ∆G0exp values for all
inhibited and uninhibited systems of MMB-4 and obidoxime are tabulated in Table 3.3.
Table 3.3

A comparison of calculated free energies (kcal/mol) with experimental
values (kcal/mol) for MMB-4 and obidoxime inhibited and uninhibited
systems.

System
hAChE-sarin-MMB-4
hAChE-tabun-MMB-4
hAChE-MMB-4
hBChE-sarin-MMB-4
hBChE-tabun-MMB-4
hBChE-MMB-4
hAChE-sarin-obidoxime
hAChE-tabun-obidoxime
hAChE-obidoxime
hBChE-sarin-obidoxime
hBChE-tabun-obidoxime
hBChE-obidoxime

∆ATI
-9.2
-5.8
-7.6
-8.3
-15.5
-6.8
-5.4
-9.6
-5.1
-14.0
-10.3
-10.4

RTln(Vo/Vs)
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2
-2.2

∆A0
-7.0
-3.6
-5.4
-6.1
-13.3
-4.6
-3.2
-7.4
-2.9
-11.8
-8.1
-8.2

∆G0exp
-3.9a
-3.6a
--4.2b
---6.2c
-5.1d
--4.1b
-4.0b
--

∆A0 - ∆G0exp
-3.1
0
--1.9
--3.0
-2.3
--7.7
-4.1
--

a = Ref. 266, b = Ref. 265, c = Ref. 264, and d = Ref. 267
Except for hAChE-tabun-MMB-4, the ∆A0 values of all the inhibited systems with
MMB-4 were lower than hAChE-MMB-4 and hBChE-MMB-4. The ∆Ao values of all
the inhibited systems with obidoxime were lower than hAChE-obidoxime. Similarly,
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among all the inhibited systems of obidoxime, only the ∆Ao value of hBChE-tabunobidoxime was lower than hBChE-obidoxime. Based on the ∆Ao values, MMB-4 binds
more efficiently than obidoxime to hAChE-sarin and hBChE-tabun systems. The
obidoxime binds more effectively to hAChE-tabun and hBChE-sarin systems compared
to MMB-4. In case of uninhibited systems, MMB-4 displayed the lowest binding energy
for hAChE and obidoxime for hBChE.
The computational and experimental standard free energy values of hAChEtabun-MMB-4 are equal. The differences between the calculated and experimental free
energies for hAChE-sarin-MMB-4, hBChE-sarin-MMB-4, hAChE-tabun-obidoxime, and
hBChE-tabun-obidoxime are within 4.2 kcal/mol. For hAChE-sarin-obidoxime, the
experimental value was lower than TI’s value by 3 kcal/mol. The accuracy of the
estimated ∆Ao values for all the inhibited systems of MMB-4 and obidoxime can be
considered to be at the ff99 forcefield limit. Usually, the binding free energies calculated
using TI or FEP will be closer to the experimental values (within 1-2 kcal/mol).270-273
However, in our studies, most of the calculated ∆Ao values lie outside that range.
This can be a forcefield issue, as there are some known problems with the ff99
forcefield. During longer simulations (some 10’s of ns), the ff99 forcefield overstabilizes the conformations of alpha-helical regions, and hence, it may structurally or
energtically affect the secondary structure of a protein.274 These issues were later
addressed by introducing the ff99SB forcefield.274 Therefore, we have chosen the
ff99SB forcefield for the PON1 studies discussed later. Out of all the inhibited systems
of MMB-4 and obidoxime, a large energy difference (-7.7 kcal/mol) was observed only
in hBChE-sarin-obidoxime. Apart from the forcefield limitation, this difference may also
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arise due to the errors in the experiment. Therefore, we suggest that the related
experiments for hBChE-sarin-obidoxime system be reconsidered.
The free energy of binding calculated using TI or FEP methods are incredibly
expensive and time consuming. For each system (inhibited or uninhibited systems of
MMB-4 or obidoxime), the electrostatic and van der Waals contributions were
individually calculated using a seven point numerical integration, and for each numerical
integration point a 10 to 20 ns simulation was performed. A total of 7×2 numerical
integration points (electrostatic + van der Waals) was performed for each individual
system. All the TI calculations were performed at the High Performance Computing
Collaboratory at Mississippi State University. We had an access to a total of 60
processors.
For a given numerical point, it took one day to perform a 1 ns simulation using 4
processors. So, ideally it takes 20 days to perform a 20 ns simulation for each numerical
integral of a system. By running parallel jobs (i.e. using 4 processors, a 1 ns simulation
was performed for each numerical point, and hence a total of 56 processors were used to
achieve a 1 ns simulation for 14 numerical points of a system in 1 day) a 20 ns simulation
for all numerical integration points of a system can be achieved in 20 days. The TI
calculations were performed for 12 different systems (4 inhibited and 2 inhibited systems
of MMB-4 and obidoxime), and thereby it takes 240 days of wall clock time to complete
all the calculations. However, it took two years to successfully finish all the desired
simulations.
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CHAPTER IV
BINDING FREE ENERGIES OF OXIMES CALCULATED USING SOLVENT
CONTINUUM MODELS AND NORMAL MODE ANALYSES

As mentioned earlier, the protein-ligand binding free energies calculated using
FEP or TI methods are computationally expensive and time consuming. Therefore, we
could not perform TI calculations for inhibited and uninhibited systems of 2-PAM and
HI-6. Hence, the continuum solvent models were explored, which are computationally
much less expensive than TI. The binding enthalpies (∆H) were calculated using
Molecular Mechanics Generalized Born Surface Area (MM-GBSA) and Molecular
Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) methods, and the TΔS
contributions were evaluated using normal mode analyses. The binding free energies
were estimated using the above mentioned methods for inhibited and uninhibited systems
with 2-PAM, MMB-4, HI-6, and obidoxime. Finally, the calculated binding free energy
values for all MMB-4 and obidoxime systems were compared with the TI results.
4.1

Computational methods
The ∆H values and normal mode analyses were calculated with the MMPBSA.py

script using AmberTools1.5275 and the ff99 forcefield.249 For the solvation energy the
electrostatic and hydrophobic interactions were calculated separately. The electrostatic
interactions are estimated by using Poisson-Boltzmann or Generalized Born equations,
67

and the hydrophobic interactions are calculated using solvent-accessible-surface-areadependent terms.276
For each system, the last 5 ns of the explicit solvent sampling process was
considered, and a total of 250 snapshots were generated, i.e., one snapshot for every 20
ps. The MMPBSA.py script automatically identifies the corresponding residues of
complex, receptor, and ligand within a given complex system. An individual enthalpy
value was calculated for each of them (complex, receptor, and ligand). Finally, ∆H is
determined using the following equation.
.

(4.1)

The ΔH calculated using the MMPBSA.py script is a sum of the internal energy
(ΔEforcefield) and the free energy of solvation (ΔGsolv = ΔGelec + ΔGvdw + ΔGcavity), as shown
in Eq.’s 2.45-2.47. Since the calculated value includes entropic terms such as cavity
formation and hydrophobic effects observed during solute-solvent interactions, the
obtained value (ΔH) is not exactly a binding enthalpy. In the computational community
the sum of ΔEforcefield and ΔGsolv is commonly referred as ΔH. The calculated ΔH values
cannot be compared with the experimental binding enthalpies, measured using isothermal
calorimetric titrations. The ΔS of TΔS term calculated using normal mode analysis
specifically refers to only the change in the entropy of the substrate and receptor as they
bind. The majority of the protein-ligand binding entropic effects are included in the ΔH
term.
The normal mode analysis is memory intensive and time consuming. Hence,
initially, the TΔS values were calculated using 10, 15, 20, and 25 snapshots for various
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systems. In the tested systems, the calculated T∆S values using 15, 20, and 25 snapshots
were within ±1 kcal/mol of the value obtained using 10 snapshots. So, given the number
of systems, we decided to use 10 snapshots for each system. Again, the last 5 ns of the
explicit solvent sampling process were considered for the analysis. During the entropy
evaluation (T∆S), all systems were initially minimized until the root mean square of the
gradient vector was less than 0.0009 kcal/mol/Å. Finally, the average TΔS value was
calculated using all generated snapshots.
4.2
4.2.1

Results and discussions
Binding enthalpy calculations
The binding enthalpies values (∆HGBSA and ∆HPBSA) and free energy values

(∆GGBSA and ∆GGBSA) for the inhibited and uninhibited systems of 2-PAM, MMB-4, HI-6,
and obidoxime are tabulated in Table 4.1. ∆HGBSA values of all the inhibited systems of
2-PAM (except hAChE-tabun-2-PAM) were lower than the corresponding values for the
uninhibited systems, whereas only the ∆HPBSA values of hAChE-sarin-2-PAM and
hBChE-sarin-2-PAM were lower than hAChE-2-PAM and hBChE-2-PAM.
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Table 4.1

Binding enthalpies (kcal/mol), TΔS values (kcal/mol), and calculated free
energies (kcal/mol) of 2-PAM, MMB-4, HI-6, and obidoxime systems.

System
hAChE-sarin-2-PAM
hAChE-tabun-2-PAM
hAChE-2-PAM
hBChE-sarin-2-PAM
hBChE-tabun-2-PAM
hBChE-2-PAM
hAChE-sarin-MMB-4
hAChE-tabun-MMB-4
hAChE-MMB-4
hBChE-sarin-MMB-4
hBChE-tabun-MMB-4
hBChE-MMB-4
hAChE-sarin-HI-6
hAChE-tabun-HI-6
hAChE-HI-6
hBChE-sarin-HI-6
hBChE-tabun-HI-6
hBChE-HI-6
hAChE-sarin-obidoxime
hAChE-tabun-obidoxime
hAChE-obidoxime
hBChE-sarin-obidoxime
hBChE-tabun-obidoxime
hBChE-obidoxime

∆HGBSA
-14.1 ± 1.6
-2.8 ± 1.7
-8.4 ± 1.6
-17.5 ± 2.7
-8.7 ± 1.6
-8.4 ± 2.2
-11.8 ± 2.3
-14.7 ± 2.5
-14.1 ± 2.0
254.7 ± 6.7
-21.2 ± 2.6
-11.7 ± 1.8
-11.2 ± 1.8
-9.5 ± 3.1
-22.3 ± 3.3
-18.0 ± 2.3
-15.3 ± 4.1
-15.4 ± 3.6
-19.9 ± 2.2
-15.4 ± 2.4
-3.5 ± 2.1
266.7 ± 85.7
-23.2 ± 2.9
-20.6 ± 2.5

∆HPBSA
-13.5 ± 2.3
-4.3 ± 2.0
-10.1 ± 2.2
-13.7 ± 5.1
-5.4 ± 3.4
-10.6 ± 3.3
-19.3 ± 3.1
-11.5 ± 4.0
-8.6 ± 4.8
5.4 ± 7.4
-14.7 ± 3.9
-19.5 ± 2.6
-15.4 ± 2.3
-13.9 ± 4.1
-24.2 ± 3.7
-20.9 ± 3.5
-13.5 ± 4.5
-14.8 ± 5.6
-19.8 ± 4.3
-20.5 ± 2.9
-9.8 ± 3.4
14.8 ± 8.9
-24.9 ± 4.5
-25.3 ± 3.9

T∆S
-13.9 ± 5.3
-13.2 ± 1.4
-20.1 ± 7.7
-13.3 ± 5.1
-14.3 ± 3.5
-13.3 ± 6.6
-19.6 ± 4.2
-20.4 ± 5.5
-18.4 ± 4.1
-19.5 ± 7.2
-21.2 ± 2.7
-22.4 ± 5.0
-10.6 ± 6.8
-17.8 ± 7.2
-25.4 ± 6.4
-23.8 ± 4.5
-25.9 ± 7.4
-18.1 ± 10.5
-19.9 ± 6.1
-18.9 ± 5.9
-18.7 ± 7.4
-21.2 ± 9.5
-25.5 ± 5.6
-13.5 ± 9.1

∆GGBSA
-0.2
10.4
11.7
-4.2
5.6
4.9
7.7
5.7
4.3
274.1
0.0
10.7
-0.6
8.3
3.1
5.7
10.7
2.7
0.0
3.5
15.2
287.9
2.4
-7.1

∆GPBSA
0.4
8.9
10.0
-0.4
8.9
2.7
0.3
8.9
9.9
24.9
6.6
2.9
-4.8
3.9
1.2
2.9
12.4
3.3
0.1
-1.6
8.9
36.0
0.6
-11.8

The ΔHGBSA values of hAChE-sarin-MMB-4, hAChE-tabun-MMB-4, and
hBChE-tabun-MMB-4 were lower than hBChE-MMB-4. Similarly, the ΔHPBSA values of
all the inhibited systems of MMB-4 (except hBChE-sarin-MMB-4) were lower than
hAChE-MMB-4. However, the ΔHPBSA of all inhibited systems of MMB-4 were higher
than the hBChE-MMB-4 value.
In the case of HI-6, only the hBChE-sarin-HI-6 system’s ∆HGBSA value was lower
than the hBChE-HI-6 value. The ∆HPBSA values of hAChE-sarin-HI-6 and hBChE-sarinHI-6 were lower than hBChE-HI-6. Both ∆HGBSA and ∆HPBSA values of hAChE-HI-6
were lower compared to all inhibited systems of HI-6. The ∆HGBSA and ∆HPBSA values of
hAChE-sarin-obidoxime, hAChE-tabun-obidoxime, and hBChE-tabun-obidoxime were
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lower than hAChE-obidoxime. A common trend was not observed among the inhibited
and uninhibited systems of the reactivators.
The ∆H values of inhibited and uninhibited systems of MMB-4 and obidoxime
were lower than the corresponding TI ΔA0 values. Overall, the ∆H values were negative
except for hBChE-sarin-MMB-4 and hBChE-sarin-obidoxime. To check the accuracy of
the simulations, the ∆H values for these systems were also calculated using a three
trajectory method. Initially, the hBChE-sarin (receptor) was minimized, heated,
equilibrated, and sampled for 10 ns using an explicit solvent simulation as described
earlier. Later, the receptor’s enthalpy was calculated using MM-GBSA and MM-PBSA
with 250 snapshots (using last 5 ns of the sampling process). Similarly, ∆H for hBChEsarin-MMB-4, hBChE-sarin-obidoxime, MMB-4, and obidoxime were individually
calculated. Using Eq. 4.1, the ∆H values were calculated for hBChE-sarin-MMB-4 and
hBChE-sarin-obidoxime. The binding enthalpies values were again positive. Hence,
these two systems appear to be problem cases for GBSA and PBSA calculations.
4.2.2

Normal mode analysis
The free energies of binding were calculated using
(4.2)
The T∆S values were mostly equal to or lower than the respective ∆HGBSA and

∆HPBSA values. As a result, the calculated free energies of binding, i.e., ∆GGBSA and
∆GPBSA, were positive, except for hBChE-sarin-2-PAM, hAChE-sarin-HI-6, and hBChEobidoxime, as shown in Table 4.1. Similarly, ∆GGBSA for hAChE-sarin-2-PAM and
∆GPBSA for hAChE-tabun-obidoxime were also negative. The ∆A0 and calculated free
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energies of binding (∆GGBSA and ∆GPBSA) for MMB-4 and obidoxime systems are
tabulated in Table 4.2. Only the ∆GGBSA/PBSA values of hBChE-obidoxime were
comparable with TI values.
Table 4.2

Comparison of free energies (kcal/mol) calculated using thermodynamic
integration, GBSA, and PBSA for all systems of MMB-4 and obidoxime.
System

∆A0

∆GGBSA

∆GPBSA

hAChE-sarin-MMB-4
hAChE-tabun-MMB-4
hAChE-MMB-4
hBChE-sarin-MMB-4
hBChE-tabun-MMB-4
hBChE-MMB-4
hAChE-sarin-obidoxime
hAChE-tabun-obidoxime
hAChE-obidoxime
hBChE-sarin-obidoxime
hBChE-tabun-obidoxime
hBChE-obidoxime

-7.0
-3.6
-5.4
-6.1
-13.3
-4.6
-3.2
-7.4
-2.9
-11.8
-8.1
-8.2

7.7
5.7
4.3
274.1
0
10.7
0
3.5
15.2
287.9
2.4
-7.03

0.3
8.9
9.9
24.9
6.6
2.9
0.1
-1.6
8.9
36.0
0.6
-11.8

One of the major challenges with the present MD simulations is to accurately
calculate protein-ligand entropies of binding.277 The normal mode analysis treats various
modes of a protein using the harmonic oscillator approximation. Usually, the low
frequency modes correspond to large motions of a biological system, and these motions
are not well described using the harmonic oscillator approximation. Hence, the entropy
contribution with respect to these modes must be approximately calculated. The entropy
of vibration is calculated using Eq. 2.56. The second term in the summation plays an
important role in estimating the Svib value. As ʋ approaches zero, i.e. low frequency, the
exponential term becomes unity, the logarithm term goes to negative infinity, and Svib
becomes positive infinity. On the other hand as ʋ 0, the first term goes to 1. So, there

72

exists a fundamental problem for calculating the vibrational entropy for low frequency
modes.
While performing the normal mode analysis, in all the snapshots of inhibited or
uninihibited systems of 2-PAM, obidoxime, HI-6, and MMB-4 the vibrational
frequencies less than 10 cm-1 were observed. For example in one of the snapshot of
hAChE-sarin-MMB-4 a few low frequencies, i.e. 1.826 cm-1, 2.222 cm-1, 3.337 cm-1,
3.480 cm-1, 3.613 cm-1, etc. were observed. If the algorithm makes a slight error in
calculating the vibrational entropies with respect to these low frequencies, the Svib term
blows up due to reason explained earlier. Therefore, we believe that the present
algorithms cannot effectively estimate the vibrational entropies due to this reason. As a
result, the calculated T∆S values are lower than or equal in magnitude to the ∆H values in
our systems. In general, the normal mode analysis is performed to explore the large
motions or conformational changes of a biomolecule.278
The reactivators MMB-4, HI-6, and obidoxime are structurally similar. Hence,
we have assumed that these oximes can have a similar change in a binding entropy value
(TΔS) when they bind to hAChE or hBChE. So, using the presumably accurate TI ∆A0
results and the binding ∆H values calculated with MM-GBSA and MM-PBSA, the T∆S
values were estimated for the MMB-4 and obidoxime systems. The hBChE-sarin-MMB4 and hBChE-sarin-obidoxime systems were excluded, as their ∆H values were positive.
The T∆S values were estimated using Eq. 4.3 and the corresponding ∆S values are
tabulated in Table 4.3,
.
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(4.3)

Table 4.3

∆S values of MMB-4 and obidoxime systems (cal mol-1 K-1)

System
hAChE-sarin-MMB-4
hAChE-tabun-MMB-4
hAChE-MMB-4
hBChE-tabun-MMB-4
hBChE-MMB-4
hAChE-sarin-obidoxime
hAChE-tabun-obidoxime
hAChE-obidoxime
hBChE-tabun-obidoxime
hBChE-obidoxime

∆SGBSA
- 16.0
- 37.0
- 29.0
- 26.3
- 23.7
- 55.7
- 26.7
- 2.0
- 50.3
- 41.3

∆SPBSA
- 40.7
- 26.3
- 10.3
- 4.3
- 50.0
- 55.3
- 43.7
- 23.0
- 56.3
- 57.0

The average ∆S value calculated using ∆SGBSA values was –30.8 cal mol-1K-1.
The ∆SPBSA value was -36.7 cal mol-1 K-1. The average ∆S values were used to estimate
free energies (ΔGGBSA/PBSA) using Eq. 4.4 for MMB-4 and obidoxime systems (except
hBChE-sarin-MMB-4 and hBChE-sarin-obidoxime). ΔA0 and estimated ΔGGBSA and
ΔGPBSA values for MMB-4 and obidoxime systems are tabulated in Table 4.4,
(4.4)
The estimated ΔGGBSA and ΔGPBSA for hAChE-obidoxime and ΔGPBSA of hAChEMMB-4 were positive. The ΔGGBSA values for all MMB-4 systems were higher than their
corresponding ΔA0, and ΔGPBSA were also higher except for hBChE-MMB-4. On the
other hand, ΔGGBSA and ΔGPBSA of hBChE-tabun-obidoxime and hBChE-obidoxime, and
ΔGGBSA of hAChE-sarin-obidoxime were lower than ΔA0.
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Table 4.4

A comparison of free energies of binding (kcal/mol) calculated using ΔA0
and estimated free energies (ΔGGBSA/PBSA) for MMB-4 and obidoxime
systems (kcal/mol).

System
hAChE-sarin-MMB-4
hAChE-tabun-MMB-4
hAChE-MMB-4
hBChE-tabun-MMB-4
hBChE-MMB-4
hAChE-sarin-obidoxime
hAChE-tabun-obidoxime
hAChE-obidoxime
hBChE-tabun-obidoxime
hBChE-obidoxime

ΔA0
-9.2
-5.8
-7.6
-15.5
-6.8
-5.4
-9.6
-5.1
-10.3
-10.4

ΔGGBSA
-2.6
-5.5
-4.9
-12.0
-2.5
-10.7
-6.2
5.7
-14.0
-11.4

ΔGPBSA
-8.3
-0.5
2.4
-3.7
-8.5
-8.8
-9.5
1.2
-13.9
-14.3

ΔGGBSA and ΔGPBSA are the estimated free energies using Eq. 4.4.
The free energies for all HI-6 systems were estimated using Eq. 4.4 and are
tabulated in Table 4.5. The estimated free energies (ΔGGBSA/PBSA) were negative for all
the inhibited and uninhibited systems of HI-6. The estimated ΔGGBSA/PBSA values for
hAChE-sarin-HI-6 were higher than ΔGexp. Whereas, the estimated free energies
(GBSA/PBSA) for hBChE-sarin-HI-6 were lower than their corresponding experimental
values.
Further, ΔGGBSA/PBSA was also estimated for all 2-PAM systems as shown in Table
4.5. The ΔGGBSA/PBSA values for hAChE-sarin-2-PAM and hBChE-sarin-2-PAM were
negative. For the remaining 2-PAM systems the estimated free energies were positive.
The estimated ΔGGBSA/PBSA values for hAChE-sarin-2-PAM and ΔGPBSA for hBChE-sarin2-PAM were higher than the experimental free energies. 2-PAM is not structurally
similar to MMB-4, HI-6, and obidoxime. However, the free energies determined using
Eq. 4.4 for all 2-PAM systems are our best estimates, better than the ones that were
previously calculated using Eq. 4.2.
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Table 4.5

A comparison of estimated free energies ΔGGBSA/PBSA (kcal/mol) with the
experimental free energies (kcal/mol) for HI-6 and 2-PAM systems.
System

GBSA
ΔGestimated

PBSA
ΔGestimated

ΔGexp

-2.0
-0.3
-13.1
-8.8
-6.1
-6.2
-4.9
6.4
0.8
-8.3
0.5
0.8

-4.4
-2.9
-13.2
-9.9
-2.5
-3.8
-2.5
6.7
0.9
-2.7
5.6
0.4

-5.9a
---3.6b
---6.3a
-4.4c
--4.5b
---

hAChE-sarin-HI-6
hAChE-tabun-HI-6
hAChE-HI-6
hBChE-sarin-HI-6
hBChE-tabun-HI-6
hBChE-HI-6
hAChE-sarin-2-PAM
hAChE-tabun-2-PAM
hAChE-2-PAM
hBChE-sarin-2-PAM
hBChE-tabun-2-PAM
hBChE-2-PAM

a = Ref. 264, b = Ref. 265, and c = Ref. 84
The root mean square (RMS) error of ΔA0TI, ΔGcalculated (using Eq. 4.2), and
ΔGestimated for the inhibited systems of MMB-4, obidoxime, HI-6, and 2-PAM were
calculated with respect to the experimental free energies and are tabulated in Table 4.6.
ΔA0TI RMS error for MMB-4 systems was lower than that of the obidoxime’s. The RMS
error of estimated ΔGGBSA was lower than the ΔGPBSA value the for MMB-4 systems. On
the other hand, the RMS errors of estimated ΔGGBSA/PBSA were equal for the obidoxime
and HI-6 systems. In the case of the HI-6 and 2-PAM systems, the RMS errors for
ΔGestimated were lower than for ΔGcalculated.
Table 4.6

Root mean square error of ΔA0TI, ΔGcalculated, and ΔGestimated values for the
inhibited systems of MMB-4, obidoxime, HI-6 and 2-PAM (kcal/mol).
ΔA0TI

ΔGcalculated
GBSA
PBSA
MMB-4
2.1
160.9
18.4
Obidoxime 4.8
146.1
20.5
HI-6
7.6
4.7
2-PAM
9.2
8.9
ΔGcalculated values are calculated using Eq. 4.2
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Reactivator

ΔGestimated
GBSA
PBSA
1.6
3.8
6.4
6.4
4.6
4.6
6.7
6.9

4.2.3

MM-GBSA per-residue contribution
One of the advantages of the MM-GBSA calculation is that the binding enthalpy

can be decomposed into per-residue contributions. The decomposition analysis can be
used to identify the residues that display favorable or unfavorable interactions with the
reactivators. The per-residue decomposition analyses for 2-PAM, MMB-4, HI-6, and
obidoxime inhibited and uninhibited systems are tabulated in Table 4.7. The
decomposition analysis was not performed for hBChE-sarin-MMB-4 and hBChE-sarinobidoxime systems, as their corresponding ∆HGBSA values were unphysical.
Table 4.7

Per-residue decomposition analyses of inhibited and uninhibited systems of
2PAM, MMB-4, HI-6, and obidoxime.

System
hAChE-sarin-2PAM
hAChE-tabun-2PAM
hAChE-2PAM
hBChE-sarin-2PAM
hBChE-tabun-2PAM
hBChE-2PAM
hAChE-sarin-MMB-4
hAChE-tabun-MMB-4
hAChE-MMB-4
hBChE-tabun-MMB-4
hBChE-MMB-4
hAChE-sarin-HI-6
hAChE-tabun-HI-6
hAChE-HI-6
hBChE-sarin-HI-6
hBChE-tabun-HI-6
hBChE-HI-6
hAChE-sarin-obidoxime
hAChE-tabun-obidoxime
hAChE-obidoxime
hBChE-tabun-obidoxime
hBChE-obidoxime

Favorable residues
Tyr73, Tyr333
Trp282
Glu448
Trp231, Phe398
Trp430
Glu197, Met81
Glu80, Met81, Glu198
Glu448
Glu448
Met81, Trp82, Glu198
Glu197, Met81, Glu80
Met81
Met81
Glu448, His443, Ser199
Tyr332, His438, Thr120,
Tyr440
Met81, Trp82
Met81
Tyr129, Glu198
Glu448, Met81
Glu80
Glu443, Trp82, Met81
Glu197

Unfavorable residues

Arg459
Arg429
Arg459
Lys131
Arg424, Lys427
Arg429
Arg459
Arg459
Lys427
Lys323
Arg424, Lys427
Arg459
Arg459, Arg429
Arg459
Lys131
Arg424, Lys427

The residues whose enthalpy values are greater than 0.3 kcal/mol are listed under
the unfavorable category and those less than -1.5 kcal/mol as favorable interactions. In
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the case of 2-PAM systems, the residues which have displayed unfavorable interactions
with the reactivator did not fall within the considered range. Therefore, only residues
which have displayed favorable interactions are reported in Table 4.7.
In all the systems a lysine or arginine displayed an unfavorable interaction with
the oxime. The reactivators, lysine, and arginine are all positively charged and therefore
repel each other. The residues under the favorable interactions category interacted with
the reactivators in the form of hydrogen bonds, van der Waals interactions, or π-π
interactions. Hence, these residues are within the vicinity of the active site. The residues
which have shown unfavorable interactions can be from any part of the protein. The
residues which have exhibited favorable and unfavorable interactions with the reactivator
in hAChE-sarin-2-PAM, hAChE-sarin-MMB-4, hAChE-sarin-HI-6, and hAChE-sarinobidoxime are shown in Figures 4.1, 4.2, 4.3, and 4.4.
It was observed that 2-PAM, MMB-4, HI-6, and obidoxime have commonly
exhibited favorable interactions with Met81 and unfavorable interaction with Arg459. A
strong electrostatic interaction between Met81 and the reactivator was observed in many
systems. The S of the Met81 and one of the pyridinium rings of the reactivator had
strong electrostatic interactions, as shown in Figure 4.5.
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Figure 4.1

2-PAM displaying favorable and unfavorable interactions with various
residues of hAChE-sarin-2-PAM

Figure 4.2

MMB-4 displaying favorable and unfavorable interactions with various
residues of hAChE-sarin-MMB-4
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Figure 4.3

HI-6 displaying favorable and unfavorable interactions with various
residues of hAChE-sarin-HI-6

Figure 4.4

Obidoxime displaying favorable and unfavorable interactions with various
residues of hAChE-sarin-obidoxime
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Figure 4.5

The electrostatic interaction between the S atom of Met81 and the
pyridinium ring of MMB-4 in hAChE-sarin-MMB-4
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CHAPTER V
DOCKING STUDIES OF HUMAN PARAOXONASE1

Some research groups have recently analyzed (experimentally and
computationally) the mechanism by which an organophosphate gets hydrolyzed in the
active site of PON1.123,128,137 These studies were done using the crystal structure of
rePON1. A hydroxide ion (formed from a water molecule) was taken as the nucleophile
to explore various organophosphate hydrolysis mechanisms. The main goal of this
project was to identify a stronger nucleophile than water to enhance the hydrolysis of
organophosphates present in the active site of human PON1 (hPON1). This work was
done in collaboration with Dr. Janice Chambers’ group (Department of Basic Science,
College of Veterinary Medicine at Mississippi State University) and Dr. Howard W.
Chambers’ group (Department of Biochemistry, Molecular Biology, Entomology, and
Plant Pathology at Mississippi State University).
Dr. Howard Chambers’ group has synthesized surrogates of sarin (3, 5, 6-trichloro2-pyrindinyl isopropyl methylphosphonate (TIMP) and 4-nitrophenyl isopropyl
methylphosphonate (NIMP)) and VX (3, 5, 6-trichloro-2-pyridinyl ethyl
methylphosphonate (TEMP) and 4-nitrophenyl ethyl methylphosphonate (NEMP)) as
shown in Figure 5.1. The experimentally synthesized compounds and chloropyrifos-oxon
(Cpo) are structurally similar and since Cpo is a known good substrate for hPON1, we
were interested in exploring the binding affinities and interactions of Cpo with various
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oximes. This analysis will be helpful to understand the interactions between an
organophosphate and an oxime present in the active site of hPON1.

Figure 5.1

Structures of 1) TIMP, 2) NIMP, 3) TEMP, and 4) NEMP

Since the crystal structure of hPON1 was unavailable, we have built 3D structures
of Q192 and R192 forms of hPON1. The docking studies were performed using the
modeled hPON1 structures, Cpo, and various oximes.
5.2

Computational details
The primary sequence of hPON1 was taken from the UniportKB/Swiss-Port

server279 and was submitted to the SWISS-MODEL online server.280,281 The tertiary
structure of (Q192) hPON1 was generated by SWISS-MODEL using PDB ID: 3SRG
(rePON1), as a reference template.128 The H1 loop (residues 1-18) was missing in the
crystal structure. Therefore, the H1 loop was generated using MODELLER282 and was
placed at its appropriate position in the modeled hPON1 structure. The glutamine at
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position 192 of the Q192 form of hPON1 was replaced by arginine to obtain the R192
polymorphism.
The modeled structures were initially minimized for 2500 steps. Then they were
heated (10-300 K) for 50 ps using Amber12283 and the ff99SB274 forcefield with a 12 Å
cutoff. They were further equilibrated for 1 ns using an implicit solvent model. The
equilibrated structures were then cooled to 0 K, by decreasing the temperature by 100 K
for every 25 ps. The resultant structures were submitted to the H++ server250,251 to obtain
the protonation states of the titratable residues and total charge of the protein.
5.2.1

Explicit solvent model simulations
Explicit solvent model simulations were performed using Amber12 and the

ff99SB forcefield. Using tleap, hPON1 (Q192/R192) was placed in a rectangular box
and solvated with TIP3P257 water molecules. The Q192 form of hPON1 was neutralized
by adding 10 Na+ ions and the R192 form with 9 Na+ ions. Both the systems were
initially minimized for 2500 steps by restraining the protein with a force constant of 500
kcal/mol·Å2. The whole systems were minimized for another 2500 steps without any
restraints. Then, the systems were heated for 50 ps from 10K to 300 K under NVT
conditions with a force constant of 10 kcal/mol·Å2 on the protein. Next, they were
equilibrated for 450 ps at 300 K under NPT conditions. Finally, both systems were
sampled for 30 ns under NVT conditions. During the equilibration and sampling process,
hydrogens were constrained using the SHAKE algorithm,258,259 and a constant
temperature was maintained using Langevin dynamics with a collision frequency of
1.0 ps-1.181 The electrostatic interactions were handled using Particle Mesh Ewald260-262
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under periodic boundary conditions with a 12 Å cutoff. All the dynamics were
performed with a time step of 1 fs.
5.2.2

Docking studies of chloropyrifos-oxon (Cpo)
Using the last 2 ns of the sampling process of (Q192/R192) hPON1, 20 snapshots

were generated (1 snapshot for every 100 ps) with the mmpbsa.pl script of Amber12.
The water molecules and counter ions were removed from the generated snapshots. Also,
a conformational analysis of Cpo was performed using the MMFFaq284 forcefield in
Spartan’10. The lowest energy conformer was chosen and was then optimized using HF
and the 6-31G* basis set with Q-Chem 3.2.151 The partial atomic charges were generated
using the restrained electrostatic potential approach.253 The optimized ligand was docked
into the active site of the generated snapshots. All the docking studies were performed
using Autodock Vina.285
During the docking studies, the surface loop (residues 72-79) of hPON1 was
made flexible, while rest of the protein was treated as rigid. The orientation of Cpo and
its interaction with the catalytic Ca2+ ion (Ca1) and with the active site residues were
visualized using VMD.255 In the Q192 form of hPON1, the O on P=O of Cpo was facing
towards or away from Ca1. The distance between O (P=O) atom of Cpo and Ca1 was
more than 10 Å when the O on P=O of Cpo was facing away from Ca1. In 11 snapshots
of the Q192 system, the Cpo was found close to Ca1, and the O of P=O was facing
towards Ca1. Out of those snapshots, the system in which the distance between O on
P=O of Cpo and Ca1 was the minimum was chosen as Case 1. In the remaining Q192
systems (9 snapshots), the structure in which the distance between O (P=O) atom of Cpo
and Ca1 was the maximum was selected as Case 2.
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In the case of the R192 docking studies, in all the snapshots Cpo was interacting
with Ca1 or with the structural Ca2+ ion (Ca2). The Ca2 is located in the top portion of
the central tunnel, and Ca1 is situated in the bottom part. The Cpo conformer in which
the distance between O (P=O) and Ca1 was the minimum was chosen as Case 3.
Similarly, the conformer where the distance between O (P=O) of Cpo and Ca2 was the
minimum was selected as Case 4. Hence, in both hPON1 systems two unique Cpo
conformers were considered.
The chosen structures (Q192/R192 + Cpo) were again placed in a rectangular box
and solvated with TIP3P water molecules. The counter ions were added to neutralize the
systems. The Amber gaff forcefield256 was used to describe Cpo. The systems were
minimized, heated, equilibrated, and sampled (25 ns) using a similar procedure to that
mentioned earlier.
5.2.3

Docking studies of neutral and monopyridinium oximes
Out of the four explicitly sampled systems, Cpo was closely interacting with Ca1

only in Case 1 and Case 3. Therefore, these equilibrated systems were considered for
further docking studies. Again, using the last 2 ns of the sampling process, four
snapshots were generated for each system.
Meanwhile, Dr. Janice Chambers’ group had tested 26 neutral oximes and various
monopyridinium oximes to analyze the hydrolysis of TIMP, NIMP, TEMP, and NEMP
bound to hPON1 using an in vitro human serum model. Among the neutral oximes only
pinacolone oxime showed any increase in hydrolysis activity, and this increase was only
5%. However, some of the monopyridinium oximes showed larger increases in
hydrolysis rates. A detailed explanation is provided in the next section.
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All the oximes were modeled using Spartan’10 and the conformational analyses
were performed using the MMFFaq.284 For each system, a lowest energy conformer was
chosen. Then, the selected conformers were individually docked to the generated
snapshots of Case 1 and Case 3 systems. During the docking studies, only the Cpo was
made flexible; rest of the system was rigid. Gasteiger charges were used as the partial
atomic charges for all ligands.286 The ligand alignment, its orientation, and its
interactions with Cpo, Ca1 or Ca2, and also with the active site residues were visually
inspected using VMD.
5.3
5.3.1

Results and discussion
Explicit solvent simulations of hPON1
The generated Q192 and R192 forms of hPON1 were equilibrated using an

explicit solvent model for 30 ns. Using an explicit solvent model, rePON1 was also
minimized, heated, equilibrated, and sampled (30 ns) using a similar procedure as
described earlier. The rePON1 crystal structure (PDB ID: 3SRG) was taken as the
starting structure, and the phosphate ion and 2-hydroxyquinoline were removed from the
active site. RMSd vs. time graphs were plotted for rePON1 and the Q192 and R192
forms of hPON1 and are shown in Figure 5.2. Since rePON1 does not have the H1 loop,
these residues were not included in the RMSd calculations for the sampled hPON1
systems. The RMSd values of the sampled hPON1 (Q192 and R192) and rePON1 were
calculated with respect to the crystal structure of rePON1 using VMD at 10, 20, and 30
ns and are tabulated in Table 5.1. The RMSd values of Q192 hPON1 at 10, 20, and 30 ns
were higher than the corresponding values of R192 hPON1 and equilibrated rePON1.
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Figure 5.2

RMSd vs. time plot of rePON1 and the Q192 and R192 forms of hPON1

Table 5.1

RMSd values of rePON1 and (Q192/R192) hPON1 equilibrated structures
calculated with respect to crystal structure of rePON1.
System
Q192
R192
rePON1 equilibrated

rePON1 crystal structure

10 ns
1.72
1.47
1.35
0

20 ns
1.95
1.72
1.26
0

30 ns
1.95
1.64
1.47
0

In the Q192 polymorph, Ca1 was in coordination with Glu53, Asp54, His115,
Asn168, and Asp169, as shown in Figure 5.3. Ca1 was closely interacting with Glu53,
Asp54, and Asp269 in the R192 system, as shown in Figure 5.4. Similarly, Ca2 was
close to Glu53, Asp269, Asn270, and Thr332 in the Q192 form of hPON1, and Asp169
and Asn270 in R192. The distance between Ca1 or Ca2 and the O atoms located at the δ
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and ε positions of these residues of Q192 and R192 hPON1 are tabulated in Tables 5.2
and 5.3, respectively. The distance between Ca1 and Ca2 in the Q192 system was about
4.5 Å and about 6.5 Å in R192. In both of the structures, Ca1 was located at the bottom
of the active site. Since the H1 loop was not in contact with the lipid bilayer, the loop has
taken a closed conformation to minimize contacts with the solvent molecules in the
(Q192/R192) hPON1 models.

Figure 5.3

The interaction of catalytic Ca2+ ion (Ca1) with various active site residues
in the Q192 hPON1
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Figure 5.4

Table 5.2

The interaction of catalytic Ca2+ ion (Ca1) with various active site residues
in the R192 hPON1

Distance between Ca1 or Ca2 and various O atom of active site residues in
the Q192 system.
Ca2+ ion
Ca1
Ca1
Ca1
Ca1
Ca1
Ca1
Ca2
Ca2
Ca2
Ca2

Residue
Glu53@OE
Glu53@OE'
Asp54@OD
His115@O
Asn168@OD
Asp169@OD
Glu53@OE
Asp269@OD
Asn270@OD
Thr332@O

Distance (Å)
2.68
2.78
2.52
2.66
2.70
2.49
2.62
2.84
2.69
2.82

OD = oxygen at the δ position, OE = OE' = oxygen at the ε position, and O = oxygen on
the carbonyl group
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Table 5.3

Distance between Ca1 or Ca2 and various O atom of active site residues in
the R192 system.
Ca2+ ion
Ca1
Ca1
Ca1
Ca1
Ca2
Ca2
Ca2
Ca2

Residue
Glu53@OE
Glu53@OE'
Asp54@OD
Asp269@OD
Asp54@OD
Asp169@OD
Asp169@OD
Asn270@OD

Distance (Å)
2.70
2.53
2.54
2.53
2.59
2.75
2.56
2.68

OD = oxygen at the δ position and OE = OE' = oxygen at the ε position.
5.3.2

Docking studies of Cpo
In all the generated snapshots of the Q192 system, the Cpo was found close to

Tyr71 and Ile74 or only to Ile74. For the snapshots in which the O (P=O) atom was
facing towards Ca1, the Cpo was closely interacting with Tyr71 and Ile74. When the O
(P=O) atom of Cpo was facing away from Ca1, the Cpo was adjacent to Ile74. Nine Cpo
conformers were found close to the active site entrance. Therefore, we have chosen a
conformer (Case 2) to examine whether the Cpo will block the active site entrance during
MD simulations. Similarly, in certain R192 snapshots, the Cpo was near Tyr71 and Ile74
when it was interacting with Ca1. In other cases, Cpo was close to Ca2. Hence, we have
considered a Cpo conformer which was close to Ca2 for MD simulations to analyze
whether this interaction is stable or not.
5.3.3

Explicit solvent simulations of (Q192/R192) hPON1 + Cpo
The selected complex (Q192/R192 + Cpo) systems were equilibrated for 25 ns

using an explicit solvent model. RMSd vs. time graphs were plotted for all systems and
are shown in Figure 5.5. During the entire simulation, Cpo did not block the active site
entrance in Case 2. In Case 4, the Cpo was in contact with Ca2. This suggests that in
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the R192 system, the Cpo can potentially bind to Ca1 or Ca2. In Case 1 and Case 3, the
Cpo was bound to Ca1; therefore, the distance between O on P=O of Cpo and Ca1 were
measured as a function of time. On average, the distance between the O (P=O) atom of
Cpo and Ca1 in Case 1 was about 6 Å and in Case 3 was 2.8 Å. Hence, the Cpo was
more tightly bound to Ca1 in the R192 system when compared to Q192.

Figure 5.5

RMSd vs. time plots of various (Q192/R192) hPON1 and Cpo systems

The binding enthalpies (∆H) for all the systems were calculated using MM-GBSA
and MM-PBSA methods and are shown in Table 5.4. The ∆H values (MM-GBSA and
MM-PBSA) were lower when the Cpo was far away from Ca1 in the (Q192) hPON1
systems (i.e. Case 2 versus Case 1). In the R192 system the MM-PBSA binding
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enthalpy value was lower when Cpo was bound to Ca1 when compared to Ca2. The
opposite result was observed using MM-GBSA.
Table 5.4

Binding enthalpies of four different (Q192/R192) hPON1 + Cpo systems.
System

Q192 hPON1 + Cpo, near Ca1
Q192 hPON1 + Cpo, away from Ca1
R192 hPON1 + Cpo, near Ca1
R192 hPON1 + Cpo, near Ca2

Case
1
2
3
4

MM-GBSA
(kcal/mol)
-24.3±2.9
-32.7±2.3
-19.3±3.2
-22.2±2.6

MM-PBSA
(kcal/mol)
-21.3±4.4
-28.0±2.6
-25.8±3.6
-20.9±3.2

The hydrolysis of Cpo bound to hPON1 mainly occurs at the catalytic Ca2+ ion
(Ca1). Therefore, to analyze the interactions between various oximes with Cpo, Case 1
and Case 3 were considered for further docking studies.
5.3.4

Neutral oximes
The experimentally tested neutral oximes are tabulated in Table 5.5. Each ligand

was individually docked to four generated snapshots of the Case 1 and Case 3 systems.
The three lowest energy conformers of each neutral oxime were chosen. The interactions
between various conformers of all ligands and Cpo were carefully inspected. In the Q192
+ Cpo system (Case 1), the ligands 1, 2, 3, 7, and 12 (Refer Table 5.5) did not exhibit
interactions with Cpo in any of the four snapshots. Similarly, in the R192 + Cpo system
(Case 3), the neutral oximes 6, 9, 10, 12, 18, 21, 22, 23, 24, 25, and 26 did not interact
with Cpo in any snapshot. None of the chosen conformers of 4-nitrobenzaldehyde oxime
(12) interacted with Cpo in either system. Overall the majority of ligands have exhibited
more favorable interactions with Case 1 than Case 3.
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Table 5.5

Structures of neutral oximes

L.No

Name

Structure

1

Acetaldehyde oxime

CH3CH=N-OH

2

Acetone oxime

3

2-butanone oxime

C

N-OH
C

N-OH

4

Cyclohexanone oxime

5

Benzaldehyde oxime

6

2-indanone oxime

7

Benzamide oxime

NH2
C N OH

8

Acetophenone oxime

CH3
C N OH

9

2-chlorobenzaldehyde oxime

N-OH

CH=N-OH

N OH

Cl
C N OH
H

10

Pinacolone oxime

11

α-isonitrosopropiophenone

12

4-nitrobenzaldehyde oxime

13

Benzoquinone dioxime

14

Pyruvicaldehyde-1-oxime

15

4'-chloroacetophenone oxime

16

2-chloroacetophenone oxime

C C N OH
O
C C N OH
CH3
O2 N

C N OH
H

HO N

N OH

O
H3C C C N OH
H
CH3
Cl
C N OH
Cl
C N OH
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Table 5.5 continued
17

3-phenoxybenzaldehyde oxime

H
C N OH
O

18

Propionaldehyde oxime
C N OH

19

4-methylbenzaldehyde oxime

20

4-nitroacetophenone oxime

21

1-naphthaldehyde oxime

22

2-naphthaldehyde oxime

23

1-acetonaphthone oxime

24

2-acetonaphthone oxime

25

4-benzyloxybenzaldehyde oxime

H3C

C N OH
H

O2N

C N OH

HC N OH

H
C N OH

CH3
C N OH

CH3
C N OH

O

26

4-(4-bromophenyl)acetophenone
oxime

L.no = ligand number
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Br

C N OH
H
C N OH
CH3

The conformers of various ligands which were closely interacting with Cpo in
Case1 and Case3 were identified. Then, the distance between the P on P=O of Cpo and
the O of C=N-OH on the neutral oximes was measured. For every oxime the conformer
with the shortest distance between the oxime O atom and the Cpo P was selected. For all
the systems, the selected distance and corresponding binding enthalpies (ΔH’s) are
tabulated in Table 5.6. Again, the ΔH values calculated using docking studies is a sum of
the internal energy of the system, electrostatic, van der Waals, hydrogen bonding
interactions, and the desolvation energy in a protein-ligand system. Hence, the estimated
ΔH is not an absolute binding enthalpy term. The binding enthalpies for all the neutral
oximes and monopyridinium oximes (discussed in the next section) are not yet
experimentally determined. However, the predicted binding enthalpies can be correlated
to the binding affinities of various neutral oximes. The binding enthalpies of various
aromatic neutral oximes in Case 1 and Case 3 were lower than the enthalpic values of the
aliphatic ones. Therefore, we predict that an aromatic neutral oxime is likely to bind with
a higher binding affinitiy to Cpo than an aliphatic ligand.
The distance between the oxime O atom and Ca1 or Ca2 are measured using a
similar criterion as mentioned above. In Q192 + Cpo docking studies, the distance
between the oxime O of the 4-methylbenzaldehyde oxime and the P atom of Cpo was
shortest (3.9 Å) among the ligands studied. This interaction is shown in Figure 5.6.
Pinacolone oxime has the next shortest distance (4.5 Å). Similarly, benzoquinone
dioxime was the closest to Cpo (4.1 Å) in Case 3, as shown in Figure 5.7.
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Table 5.6

Distance between the O atom on the oxime group of a neutral oxime and the
P atom of Cpo in various Case 1 and Case 3 systems along with their
binding enthalpy values.

Ligand
Cyclohexanone oxime
Benzaldehyde oxime
2-indanone oxime
Acetophenone oxime
2-chlorobenzaldehyde oxime
Pinacolone oxime
α-isonitropropiophenone oxime
4'-chloroacetophenone oxime
2-chloroacetophenone oxime
3-phenoxybenzaldehyde oxime
Propionaldehyde oxime
4-methylbenzaldehyde oxime
4-nitroacetophenone oxime
1-naphthaldehyde oxime
2-naphthaldehyde oxime
1-acetonaphthone oxime
2-acetonaphthone oxime
4-benzyloxybenzaldehyde oxime
4-(4-bromophenyl)-acetophenone oxime
Acetaldehyde oxime
Acetone oxime
2-butanone oxime
Cyclohexanone oxime
Benzaldehyde oxime
Benzamide oxime
Acetophenone oxime
α-isonitropropiophenone oxime
Benzoquinone dioxime
Pyruvicaldehyde oxime
4'-chloroacetophenone oxime
2-chloroacetophenone oxime
3-phenoxybenzaldehyde oxime
4-methylbenzaldehyde oxime
4-nitroacetophenone oxime
4-(4-bromophenyl)-acetophenone oxime

System
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
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Distance (Å)
5.1
8.9
8.1
7.4
9.7
4.5
8.9
8.1
8.0
8.8
4.6
3.9
6.9
9.4
8.2
8.9
9.4
8.8
8.2
9.5
8.3
9.8
9.6
8.8
7.5
9.1
9.6
4.1
8.9
11.3
9.7
11.2
11.3
12.0
8.3

∆H (kcal/mol)
-4.9
-5.1
-6.2
-5.3
-5.7
-4.8
-6.1
-5.7
-5.7
-6.9
-5.6
-5.5
-6.6
-6.9
-6.8
-7.3
-6.9
-7.1
-8.1
-3.2
-3.8
-4.0
-4.9
-5.1
-5.9
-5.5
-6.2
-5.5
-3.8
-5.4
-5.6
-6.5
-5.1
-5.8
-6.9

Figure 5.6

Interaction between Cpo and 4-methylbenzaldehyde oxime in (Q192)
hPON1 + Cpo system

Figure 5.7

Interaction between Cpo and benzoquinone dioxime in (R192) hPON1 +
Cpo system
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In Case 1 and Case 3 systems, 4-(4-bromophenyl)-acetophenone oxime has
exhibited the highest binding affinity (lowest binding enthalpy). In the Q192 + Cpo and
R192 + Cpo systems, the bulky aromatic ligands, such as 17, 21, 23, 25, etc., have shown
more favorable interactions with Cpo than the aliphatic oximes.
Apart from interacting with Cpo, the neutral oximes have also shown interactions
with Ca1 and Ca2. In Case 1 docking studies, certain conformers of various ligands were
exclusively bound to Ca1. Therefore, the distance between the O of C=N-OH of the
ligand and Ca1 were measured and tabulated in Table 5.7. Similarly, in R192 + Cpo
systems, the ligands were preferentially bound to Ca2 in all cases. Hence, the distance
between Ca2 and the O (C=N-OH) atom of the ligand were measured and shown in Table
5.8.
As mentioned earlier, the Ca2 is located in the top portion of the central tunnel,
and hence the incoming neutral oximes may have entered through the upper part of the
central tunnel and interacted with Ca2 in the R192 hPON1 + Cpo system. The
interaction between benzamide oxime (7) and Ca2 in Case 3 is shown in Figure 5.8.
However, the ligand should enter through the bottom part of the central tunnel (active
site) to hydrolyze the organophosphate. Hence, a snapshot in which a conformer of
benzamide oxime has interacted with Cpo (by entering through the active site) in the
R192 hPON1 + Cpo system is shown in Figure 5.9.
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Table 5.7

The distance between the O atom on the oxime group of a neutral oxime and
Ca1 of various Case 1 systems and their corresponding binding enthalpies.
Ligand
Acetaldehyde oxime
Acetone oxime
2-butanone oxime
Benzaldehyde oxime
2-indanone oxime
Benzamide oxime
2-chlorobenzaldehyde oxime
4-nitrobenzaldehyde oxime
Benzoquinone dioxime
Pyruvicaldehyde oxime
4'-chloroacetophenone oxime
2-chloroacetophenone oxime
4-nitroacetophenone oxime
2-acetonaphthone oxime
4-benzyloxybenzaldehyde oxime
4-(4-bromophenyl)-acetophenone oxime

Table 5.8

Distance (Å)
4.7
5.3
4.7
5.9
4.6
4.7
5.2
5.7
4.7
4.5
6.9
4.7
5.0
5.2
4.8
5.3

∆H (kcal/mol)

-3.5
-3.9
-4.2
-5.6
-6.4
-6.1
-5.4
-6.4
-6.2
-4.2
-6.0
-5.2
-6.7
-7.4
-7.9
-6.9

The distance between the O atom on the oxime group of a neutral oxime and
Ca2 of various Case 3 systems and their corresponding binding enthalpies.
Ligand
Cyclohexanone oxime
Benzaldehyde oxime
2-indanone oxime
Benzamide oxime
Acetophenone oxime
2-chlorobenzaldehyde oxime
Pinacolone oxime
α-isonitropropiophenone oxime
4-nitrobenzaldehyde oxime
Pyruvicaldehyde oxime
4'-chloroacetophenone oxime
2-chloroacetophenone oxime
3-phenoxybenzaldehyde oxime
Propionaldehyde oxime
4-methylbenzaldehyde oxime
4-nitroacetophenone oxime
1-naphthaldehyde oxime
2-naphthaldehyde oxime
1-acetonaphthone oxime
2-acetonaphthone oxime
4-benzyloxybenzaldehyde oxime

Distance (Å)
7.1
7.1
7.0
6.6
7.1
6.6
7.2
7.1
7.0
7.1
6.8
6.9
6.9
7.1
7.2
8.2
7.9
6.8
7.1
6.6
8.1
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∆H (kcal/mol)

-4.7
-5.0
-6.0
-5.6
-5.4
-5.4
-4.4
-5.8
-5.7
-3.6
-5.4
-5.2
-7.2
-5.3
-5.4
-6.0
-6.2
-6.7
-7.1
-6.8
-7.1

Figure 5.8

Interaction between benzamide oxime and Ca2 in the R192 hPON1 + Cpo

Figure 5.9

Interactions between benzamide oxime and Cpo in the R192 hPON1 + Cpo
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Various conformers of the ligands 5, 6, 7, 9, 15, 16, 20, 24, and 25 have exhibited
interactions with Cpo, Ca1, and Ca2 in both Case 1 and Case 3 systems. Therefore, the
experimentally tested neutral oximes can potentially interact with Ca1 or Ca2 along with
Cpo. On the other hand, in some of the Cpo conformers, the aromatic ring of Cpo was
blocking the O atom (C=N-OH) of the ligand during the nucleophilic attack. In other
words, the aromatic ring on Cpo and the oxime group of the ligand were aligning on the
same axis. This alignment was inhibiting the O atom from attacking the P atom of Cpo.
The interaction of neutral oximes with Ca1 or Ca2 and the hindrance of the Cpo aromatic
ring may influence the hydrolysis process.
The docking studies performed with 26 neutral ligands have shown that the
aromatic ligands exhibited higher binding affinities towards Cpo than the aliphatic
ligands in both the Q192 and R192 hPON1 systems. However, the molecular framework
attached to the oxime group was not flexible enough. As a result, the neutral oximes
were unable to orient properly while interacting with Cpo.
5.3.5

Monopyridinium oximes
Based on the above analysis and conclusions, our experimental collaborators have

synthesized and tested a series of monopyridinium oximes while varying the linker length
using a reference template as shown in Figure 5.10.

Figure 5.10

Reference template for monopyridinium oxime

where R is the linker length = (CH2)n and n = 1- 6
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The hydrolysis rate tremendously increased when the linker length was 6 (i.e., R =
(CH2)6). The monopyridinium oximes which have efficiently hydrolyzed the surrogates
of sarin (TIMP and NIMP) and VX (TEMP and NEMP) are shown in Table 5.9. The
ligands 46.15 and 46.16 have shown the highest hydrolysis rates.
Table 5.9

Structures of experimentally tested monopyridinium oximes

Ligand number
46.06
46.10
46.12

R
H3C O

O2N

O
H3C C

46.15
46.16
46.23

O

46.24
46.25

H2C
H2C O

Cl

46.28
Cl

Cl

46.43

H2
C C C

All 10 monopyridinium oximes were docked to the generated snapshots of Case 1
and Case 3 using a similar procedure to that described earlier. In Case 1 systems the
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ligands 46.10, 46.15, and 46.25 did not interact with Cpo in any of the snapshots,
whereas in Case 3 all the ligands, except 46.10, interacted with Cpo in at least one out of
the four generated snapshots. In the Q192 + Cpo systems, most of the ligands were
closer to Ca1 than to Cpo. In the R192 + Cpo system, some of the conformers of all the
ligands were found close to Ca2. The ligands 46.15, 46.28, and 46.43 have interacted
with Cpo in a majority of the snapshots. Again, the distance between the oxime O of the
ligand and the Cpo P was measured for all systems and is shown in Table 5.10.
Similarly, the distance between the oxime O and Ca1 was measured in all Case 1 systems
and tabulated in Table 5.11. The distance between the oxime O of the ligand and Ca2
was measured in all Case 3 systems and is shown in Table 5.12. The monopyridinium
oximes were closer to Ca1 in Q192 + Cpo than to Ca2 in R192 + Cpo.
Table 5.10

Distance between the O atom on the oxime group of monopyridinium oxime
and the P atom of Cpo in various Case 1 and Case 3 systems along with
their binding enthalpies.
Ligand number
46.06
46.12
46.16
46.23
46.24
46.28
46.43

System
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1
Case 1

Distance (Å)
8.9
9.4
9.5
8.4
9.5
5.6
8.4

∆H

46.06
46.12
46.15
46.16
46.23
46.24
46.25
46.28
46.43

Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3
Case 3

10.2
10.2
7.5
7.5
9.2
9.6
7.6
7.6
9.9

-7.3
-6.3
-8.0
-6.4
-7.0
-7.2
-6.8
-7.5
-6.0
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(kcal/mol)
-6.8
-7.8
-7.7
-6.9
-6.8
-8.0
-7.1

Table 5.11

Distance between the O atom on the oxime group of a monopyridinium
oxime and Ca1 of various Case 1 systems and their corresponding binding
enthalpies.

Ligand
46.06
46.10
46.12
46.15
46.16
46.23
46.24
46.25
46.28
46.43

Table 5.12

Distance (Å)
5.0
5.5
4.8
5.7
5.5
4.6
4.6
5.6
5.5
5.4

∆H

(kcal/mol)
-7.5
-7.9
-7.8
-8.4
-8.5
-8.1
-8.3
-8.5
-6.9
-8.3

Distance between the O atom on the oxime group of a monopyridinium
oxime and Ca2 of various Case 3 systems and their corresponding binding
enthalpies.

Ligand number
46.06
46.10
46.12
46.15
46.16
46.23
46.24
46.25
46.28

Distance (Å)
6.6
6.7
6.3
7.2
8.2
7.2
7.1
7.4
7.1

∆H

(kcal/mol)
-6.7
-6.3
-6.7
-7.2
-8.3
-6.9
-6.7
-7.1
-6.6

Out of all the monopyridinium oximes, 46.28 was found closest to Cpo (5.6 Å)
and also exhibited the lowest binding energy in Case 1. 46.15 and 46.16 were found
closest to Cpo (7.5 Å), and the binding energy of 46.16 was lowest in Case 3. Most of
the monopyridinium oximes conformers have more effectively interacted with Cpo in
R192 + Cpo than in Q192 + Cpo. On the other hand, many of the neutral oximes have
shown favorable interactions with Cpo in Q192 + Cpo systems. This suggests that the
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hydrolysis of an organophosphate bound to Q192 or R192 hPON1 may depend on the
nature of the oxime.
We were interested to study a new set of oximes based on a reference template, as
shown in Figure 5.11. Based on this template, tertiary and quaternary amine oximes can
be designed. Further, we estimated the relative deprotonation energy for deprotonating
the H atom present on the oxime group in tertiary, quaternary, and monopyridinium
oximes compared to a neutral oxime. All the molecules are shown in Figure 5.12. The
oximes and their corresponding anions were modeled using Spartan’10. The
conformational analyses were performed using MMFFaq. The lowest energy conformer
was chosen and optimized with M06-2X/aug-cc-pVDZ287 using 150 radial points and the
302 point Lebedev288,289 angular grid using Q-Chem 4.0.1.151 The polarized continuum
solvent model290 with a dielectric constant of 78.39 Debye was also included.

Figure 5.11

Reference template for tertiary or quaternary amine oximes
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Figure 5.12

1) Neutral oxime, 2) oxime with tertiary amine, 3) oxime with quaternary
amine, and 4) monopyridinium oxime

In each system the energy difference between a deprotonated oxime and the
oxime which has an H atom on its oxime group was calculated. Then, the resultant
energies for oximes containing tertiary amine and quaternary amine, and
monopyridinium oxime were subtracted from the neutral oxime’s deprotonation energy to
obtain relative deprotonation energies and are shown in Table 5.13. The relative
deprotonation energy of monopyridinium oxime was lowest, and the oxime containing
tertiary amine was highest. In other words, more energy is required to deprotonate the H
atom on the oxime group of the tertiary amine oxime compared to the neutral oxime.
Table 5.13

Deprotonation energies (kcal/mol) and relative deprotonation energies
(kcal/mol) of oximes containing a tertiary amine and quaternary amine, and
monopyridinium oxime calculated with respect to a neutral oxime.
Molecule

Deprotonation energy

1
2
3
4

305.3
307.6
301.6
293.4
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Relative deprotonation
energy
0
2.3
-3.7
-11.9

Similarly, less energy is required to deprotonate the H on the oxime group of the
monopyridinium oxime and the oxime containing quaternary amine compared to the
neutral oxime in the solvent medium. The H atom (on the oxime group) in the
monopyridinium oxime is more acidic than one present on the oxime-containing
quaternary amine. Hence, the hydrolysis rate of monopyridinium oximes might be higher
than the oximes containing quaternary amine. Further, the monopyridinium oximes may
hydrolyze organophosphates more efficiently than neutral oximes.
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CHAPTER VI
CONCLUSIONS

This chapter is divided into two sections: oximes as reactivators and oximes as
hydrolyzing agents.
6.1

Oximes as reactivators
All the inhibited and uninhibited systems of 2-PAM, MMB-4, HI-6, and

obidoxime were sampled using explicit solvent simulations. 2-PAM displayed hydrogen
bonding interactions with a few active site residues in all the systems except hAChEsarin-2-PAM. MMB-4 did not exhibit hydrogen bonding in hBChE-sarin-MMB-4 and
hBChE-tabun-MMB-4. Similarly, obidoxime did not display hydrogen bonding with the
active site residues in hAChE-sarin-obidoxime and hBChE-sarin-obidoxime. HI-6 did not
exhibit hydrogen bonding in hAChE-HI-6. Glu80 has shown favorable interactions with
MMB-4, HI-6, and obidoxime. 2-PAM, MMB-4, and HI-6 displayed π-π interactions
with various Tyr or Trp residues in some of the inhibited and uninhibited systems.
The calculated TI values can be considered to be accurate values at the ff99
forcefield limit. ∆A0 values of MMB-4 and obidoxime systems were lower than the
experimental values except for hAChE-sarin-obidoxime (3 kcal/mol). The RMS error of
∆A0 for the inhibited systems of MMB-4 was 2.1 kcal/mol and for obidoxime systems
was 4.8 kcal/mol. Usually, the binding free energies calculated using TI are closer to the
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experimental values (within 1-2 kcal/mol).270-273 However, in our systems, the calculated
∆Ao values were lower than experimental values. This may due to the forcefield
limitations of the ff99 forcefield.
The calculated binding enthalpies using MM-GBSA and MM-PBSA for all the
inhibited and uninhibited systems of 2-PAM, MMB-4, HI-6, and obidoxime were
negative except for hBChE-sarin-MMB-4 and hBChE-sarin-obidoxime. The ∆HGBSA and
∆HPBSA for these two systems were also calculated using a three trajectory method.
Again, positive binding enthalpies were obtained, suggesting that these systems might be
problematical for MM-GBSA and MM-PBSA calculations. The calculated ∆H values for
all the inhibited and uninhibited systems of MMB-4 and obidoxime were lower than
corresponding TI values except for the two systems mentioned above.
For all the systems the TΔS values estimated using normal mode analyses were
equal to or lower in magnitude than their corresponding binding enthalpies. As a result,
the calculated free energies of binding, i.e., ∆GGBSA and ∆GPBSA, for most of the systems
were positive. The calculated ∆GGBSA and ∆GPBSA values of all the inhibited and
uninhibited systems of MMB-4 and obidoxime were compared with the TI values.
Among all the systems of MMB-4 and obidoxime, only the ∆GGBSA and ∆GPBSA values of
hBChE-obidoxime were comparable with the corresponding TI numbers.
The normal mode analysis treats various modes of a protein using the harmonic
oscillator approximation. However, the low frequency modes are not well described by
the harmonic oscillator approximation. Hence, the present algorithms cannot effectively
estimate the vibrational entropies for the low frequency modes. Therefore, the calculated
T∆S values are lower than or equal in magnitude to the ∆H values in our systems.
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Hence, the ΔS values were estimated using ΔA0 and ΔHGBSA/PBSA values for all
MMB-4 and obidoxime systems except for hBChE-sarin-MMB-4 and hBChE-sarinobidoxime. Then, average ΔS values (ΔSGBSA and ΔSPBSA) were calculated using the
estimated binding entropies. Further, the binding free energies were estimated for HI-6
and 2-PAM systems using ΔHGBSA/PBSA and average ΔS values. For all HI-6 systems
ΔGGBSA/PBSA was negative. For the 2-PAM systems, only the ΔGGBSA/PBSA values for
hAChE-sarin-2-PAM and hBChE-sarin-2-PAM were negative. However, the estimated
free energies for the 2-PAM systems are still likely better estimates than the earlier free
energies calculated using binding enthalpies and binding entropies (TΔS) obtained using
normal mode analyses.
MM-GBSA per-residue decomposition analyses were performed for all the
inhibited and uninhibited systems of 2-PAM, MMB-4, HI-6, and obidoxime. Met81 has
commonly shown favorable interactions with the reactivator in most of the systems. The
S atom on the Met81 and one of the pyridinium rings of the reactivator had strong
electrostatic interactions. Further, lysine or arginine displayed unfavorable interactions
with the reactivators in all the systems. The reactivator, lysine, and arginine are all
positively charged and therefore repel each other.
Overall, we have used a variety of computational methods (TI, MM-GBSA, MMPBSA, and normal mode analysis) to calculate binding free energies of various
reactivators bound to inhibited systems: hAChE-sarin, hAChE-tabun, hBChE-sarin,
hBChE-tabun, and uninhibited systems: hAChE and hBChE. The free energies
calculated using TI were more accurate than the one estimated using other alternative
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methods. We have also identified various active site residues participating in hydrogen
bond, electrostatic, or π-π interactions with the reactivator.
6.2

Oximes as hydrolyzing agents
Ca1 and Ca2 were in coordination with O atom located at δ and ε positions on

various active site residues in the Q192 and R192 polymorphs of hPON1. In Q192 + Cpo
and R192 + Cpo systems, various conformers of Cpo were closely interacting with Tyr71
and Ile74. The O atom (P=O) of the Cpo was facing either towards or away from Ca1, in
case of Q192 hPON1 + Cpo. In R192 + Cpo, various conformers of Cpo were interacting
with either Ca1 or Ca2. Overall, Cpo was more tightly bound to Ca1 in R192 hPON1
than in Q192 hPON1.
Out of all the neutral oximes, 4-methylbenzaldehyde oxime and pinacolone oxime
were found closest to Cpo in Q192 + Cpo system. The distance between the P atom of
Cpo and the oxime O of 4-methylbenzaldehyde was 3.9 Å and in pinacolone oxime the
distance was 4.5 Å. Similarly, in R192 + Cpo benzoquinone dioxime was closest to Cpo
(4.1 Å). The neutral oximes containing aromatic rings have shown more favorable
interactions with Cpo than the aliphatic ones. The neutral oximes have displayed more
favorable interactions with Cpo in Q192 than with Cpo in R192.
Most of the monopyridinium oximes were found close to Ca1 in Q192 + Cpo.
The ligands have interacted with Cpo or Ca2 in R192 + Cpo. All the monopyridinium
oximes have shown more favorable interactions with Cpo in R192 + Cpo than in Q192 +
Cpo. Various conformers of neutral oximes and monopyridinium oximes have exhibited
interactions with Ca1 or Ca2 next to Cpo.

112

The relative deprotonation energies of the monopyridinium oxime and the oxime
containing a quaternary ammonium were less than the corresponding value of the neutral
oxime. Hence, the hydrolysis rate of monopyridinium oximes may be higher than the
oximes containing quaternary amine and neutral oxime. This suggests that
monopyridinium oximes can more effectively hydrolyze organophosphates than the
neutral oximes. Finally, this study was useful to understand the binding interactions
between the organophosphates and a variety of neutral and monopyridinium oximes
bound to Q192 or R192 hPON1.
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